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ABSTRACT 
The objective of this thesis was to investigate short- and long-term effects of ovarian surgery 
on the ovarian reserve of women of reproductive age. This research also considered their 
reproductive outcomes with regard to conceiving spontaneously or using assisted 
reproductive techniques (ART). We also wished to explore how women perceived the 
information they received about fertility when planning for ovarian surgery.  
In paper I, a cross-sectional study that included 106 women, we investigated patients’ 
perceptions of the fertility-related information they received as well as fertility distress prior 
to ovarian cyst surgery. Although a high proportion of the women (72 %) desired to have 
children in the future, only half recalled receiving information about the potential impact of 
surgery on fertility. In a multivariable logistic regression, desire for children was the only 
association with recalled fertility-related information. Additionally, more than half of the 
women (54 %) reported fertility distress with VAS-scores ≥ 5 prior to surgery.  
Paper II involves a prospective clinical cohort study that included 75 women planned for 
conservative ovarian cyst surgery (cystectomy, ovarian resection or unilateral oophorectomy). 
We investigated the effects of removed cysts’ histopathology on women’s ovarian reserve, 
estimated as serum concentrations of Anti-Mullerian Hormone, AMH. The AMH levels 
declined significantly from presurgery levels of 2.7 µg/L (0.2-16.9) to 1.6 µg/L (0.2-9.9) at 
three months, and the levels remained low at six months, 1.6 µg/L (0.2-8.3) (p<0.001, 
respectively). In patients who had a single cyst enucleation, a reduction was observed after 
surgery for both endometriomas and dermoid cysts. In a logistic regression, the only 
predictive factor found for the decline of AMH serum concentrations was a higher baseline 
AMH level prior to surgery.  
In paper III, we prospectively investigated the changes in AMH after a long-term post-
operative follow-up of two years in 66 of the women included in the clinical cohort study. 
The progressive post-operative decline of serum AMH concentrations continued over time. 
The AMH serum concentration significantly reduced from 2.7 µg/L at baseline to 2.0 µg/L 
at six months. We observed a further reduction to 1.0 µg/L at the two-year follow-up (p = 
0.001, respectively). Nonetheless, women who attempted pregnancy succeeded in 58 % of 
the cases. Women with normal or high AMH at baseline had a higher chance of conceiving, 
regardless of their AMH reduction over time. 
In paper IV, we examined the clinical pregnancy rate after Assisted Reproductive 
Technology (ART) in a cohort of 76 women with a history of unilateral oophorectomy 
(UO), as compared to 12879 controls. Exposed women with UO and unexposed controls 
were included at three ART Swedish clinics. In this multicentre study, single embryo 
transfer was performed in 77 % of cases; analysis showed a significant reduction of 30 % in 
the clinical pregnancy rate of women with UO compared to controls, both crude and after 
adjustment for age. 
 
Conclusion: The studies included in this thesis indicate that the ovarian reserve, estimated 
by its biochemical marker AMH, decreases significantly after conservative ovarian surgery 
for cysts in women of fertile age. The post-operative AMH decrease continues two years 
following the ovarian surgery, even though no macroscopic ovarian tissue was reported as 
being removed at the time of surgery. The reduction in AMH does not seem to affect 
fertility in women presenting with normal or high AMH serum concentrations prior to 
ovarian surgery. On the other hand, women of fertile age who had a previous surgical 
removal of one ovary had reduced chances of pregnancy, estimated as reduced clinical 
pregnancy rate after ART. Women require this important information in order to make 
decisions regarding their reproductive ability; however, our research evidenced that women 
were not properly informed of the potentially negative effects of ovarian surgery on 
reproduction. 
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1 INTRODUCTION 
Fertility and childbearing are important aspects of most women’s lives. Women today often 
delay childbearing to an age where the risk of infertility increases (1); therefore, it is critically 
important that healthcare providers give accurate and individualized information regarding 
each woman’s fecundity. When a woman is considering ovarian surgery due to benign cysts, 
medical professionals should provide adequate information regarding the effect of surgery on 
ovarian reserve. Ovarian reserve is defined as the quantity and quality of the oocytes, and it 
greatly impacts a woman’s ability to conceive. Over the last ten years, estimation of AMH 
serum concentrations has become an easily accessible hormone test evaluating the ovarian 
reserve, and it is regarded as one of the most reliable tests for this measure. With increasing 
age, both the quantity and quality of the ovarian follicle pool diminish, and AMH 
consequently decreases (2). 
When this research project started in 2010, little was known about the effects of ovarian 
surgery on female fertility. Since then, the number of publications has substantially increased, 
indicating interest in this research area. The literature suggests that a reduction of fertility 
might occur after ovarian surgery for ovarian cysts. AMH measurements have spread and 
become easier, replacing earlier and less specific hormonal tests. Today, AMH is used for 
many purposes, including predicting and evaluating the chances of success in fertility 
treatments. Clearly, AMH testing has gained a place among reproductive medicine clinicians.  
My interest in fertility and pregnancy emerged during my specialist training. I, like most 
gynaecologists, have performed minimally invasive surgery to remove ovarian cysts in young 
women. During these interventions, important questions emerged: what effects would this 
surgery have on the future fertility of patients and how could we provide adequate 
information when so little was known? During the development of this project, I recognized a 
special interest in women with a history of unilateral oophorectomy (UO), and I wished to 
investigate their chances of pregnancy. What information did these women need to make an 
informed decision? The studies designed for this project aimed to increase knowledge 
regarding the effects of ovarian surgery on ovarian reserve and fertility. If we could learn 
more about this topic, we could provide more accurate information to women in 
gynaecological care, better meeting their needs. 
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2 BACKGROUND 
2.1 FERTILITY 
Most people regard becoming a parent as highly important in their lives (3, 4). As social and 
economic development has increased during the last century, there has been a substantial 
decline in fertility rates (5). Meanwhile, age is the single most important factor affecting 
women’s fertility. In western countries, women tend to postpone their childbearing period to 
a time when age-related infertility increases. This decision increases the probability of 
involuntary childlessness and/or smaller families. Over the last 30 years, the median age of 
women at their first birth in Sweden increased from 24 to 29 years (6). A similar trend has 
been noted all over Europe, where data show an increase in median age at first birth from 
24.4 to 25.9 years of age from 1990 to 2003 (7).  
Female fertility is multifactorial, with quality and quantity of oocytes being the most 
important factor (1, 8). Other factors of importance are a normal uterine anatomy, a thick 
endometrium at time of implantation and permeable tubes. The infertility rate – defined as 
more than 12 months without clinical pregnancy – increased from 8 % among women aged 
19-26 years up to 18 % among women aged 35-39 years old (9). Sexually-transmitted 
diseases, such as chlamydia, also negatively impact fertility by reducing the tubal 
permeability and by increasing the risk of extrauterine pregnancy (10). With increasing age, 
there is a higher risk of comorbidity of benign diseases, such as endometriosis or myomas, 
which affect women’s fecundity. Endometriosis can cause infertility in 30-50 % of women 
through several proposed factors, such as adhesions, distorted pelvic anatomy and oocyte 
quality (11). Finally, the risk of cancer increases with age, and its treatment can cause 
infertility (12). 
2.2 OOCYTE DEVELOPMENT 
Oocytes are the reproductive female cells, colloquially known as eggs. The follicles include 
both the oocytes, contained in fluid, and the surrounding cell layers. The follicle fluid is rich 
in hormones and growth factors. A pre-granulosa cell layer surrounds the primordial follicle. 
In oocyte development, the primordial germ cells migrate from the yolk sac to the gonadal 
ridge, where the ovaries form. Gestational week 16 sees the formation of clusters of cells, 
known as primordial follicles. These follicles consist of the oogonia, developed from germ 
cells. After meiosis, the oogonia develop into primary oocytes during foetal life. When a 
female child is born, she has a follicle population consisting of 200000- 1milj follicles (13, 
14).  There is a gradual loss of follicles both before and after puberty. At puberty, the 
recruitment and maturation of oocytes begin. There is a transition from primordial follicles to 
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primary follicles, and thereafter, to secondary follicles and ovulation. The one follicle that 
escapes atresia will ovulate. Development from a primordial follicle to the ovulatory stage 
require several months (folliculogenesis) (15). The transition process from primordial 
follicles to primary follicles is not fully understood, but at least part of the process is 
controlled by growth factors. One group of growth factors is the transforming growth factor 
B (TGF-B) family. Secreted from the primary, secondary and small antral follicles, the Anti-
Müllerian Hormone, AMH, is a glycoprotein that is part of this TGF-B family. A 
gonadotropin-independent process stimulates oocyte growth and differentiation to antral 
follicles, which takes about 70 days. 
Figure 1. AMH and the folliculogenesis. AMH is produced by the primary, secondary and small antral follicles 
(16). 
 
Reprinted with the permission of Human Reproduction. La Marca, A., F. J. Broekmans, A. Volpe, B. C. Fauser 
and N. S. Macklon (2009). "Anti-Mullerian hormone (AMH): what do we still need to know?" Human 
Reproduction 24(9): 2264-2275. 
2.2.1 Development of a mature oocyte to achieve ovulation 
The oocyte must undergo developmental competence and maturation to be viable for 
fertilization. At the pre-antral follicle stage, the zona pellucida forms; thereafter, the process 
is gonadotropin-dependent. The process includes oocyte enlargement, vascularization and 
proliferation of granulosa cells and the theca layer. The granulosa cells can synthesize 
oestrogen when stimulated by follicle stimulating hormone (FSH). Both oestrogen and FSH 
stimulate the production of follicular fluid, antrum formation and formation of the cumulus 
oophorus, a granulosa cell layer that surrounds the oocyte. At the end of the luteal phase, just 
prior to menstruation, there is an increase of FSH, which stimulates the growth of several 
follicles. As follicles grow, more oestradiol is secreted from them, which has a negative effect 
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on the hypothalamus and the pituitary gland. This negative feedback inhibits the production 
of FSH, allowing only the follicle with the most receptors for FSH to dominate; hence, it 
grows and acquires the ability to ovulate during the luteinising hormone (LH) surge. Ability 
to convert androgens to oestrogens (aromatization) is crucial in the formation of a dominant 
follicle. With the influence of LH, the larger follicles are able to better develop and 
synthesize androgens in their theca cells. Under the influence of FSH, the androgens are 
aromatized to oestrogens in the proliferating granulosa cells. There is a higher sensitivity in 
the dominant follicle for FSH due to the increase of granulosa cells and higher FSH density. 
The negative feedback mechanism makes the smaller follicles even more clearly destined for 
atresia. The LH surge at ovulation is stimulated by the sustained production of oestrogen 
from the dominant follicle of about 15-20 mm. Oestrogen stimulates the pituitary gland to 
release LH. Ovulation can only happen in a mature follicle where the oocyte has undergone 
the final meiotic division and turned into a mature haploid oocyte with 23 chromosomes. 
Several hormones, prostaglandins and enzymes drive the process of ovulation. After 
ovulation, the ruptured dominant follicle forms the corpus luteum. In the process of corpus 
luteum formation, the theca cells luteinize into theca lutein cells and the granulosa cells into 
granulosa-lutein cells. Progesterone, synthesized from cholesterol, is secreted from the corpus 
luteum with the objective of maturing the endometrium, and it eventually sustains early 
pregnancy. If pregnancy occurs and human chorionic gonadotropin (HCG) is secreted, the 
corpus luteum will continue to produce progesterone. Otherwise, there will be a regression of 
the corpus luteum. The luteal phase lasts 14 (± 3) days (17). 
2.2.2 Menstrual cycle  
The menstrual cycle mirrors the ovarian cycle, as hormones produced from the ovaries 
stimulate and control the endometrium in the uterus. The endometrium is an important factor 
for implantation to occur. During the follicular phase, oestrogen, which is produced by the 
ovarian follicle, promotes the proliferation of the endometrium in the uterus. After ovulation, 
secretory glands develop in the endometrium under the influence of oestrogen and 
progesterone, which is secreted from the corpus luteum. At the time of implantation, around 
cycle day 21-22, the endometrium is edematous. In the absence of pregnancy, there is a fall in 
oestrogen and progesterone, leading to menstrual bleeding. When the menstrual cycle 
becomes ovulatory after puberty, the cycle tends to have a frequent interval of 28 days (18). 
The menstrual cycle length successively shortens with aging due to a progressive reduction in 
the pool of oocytes. The FSH serum concentration starts to increase, a trend that can already 
be detected in the late luteal phase; therefore, the subsequent follicular phase begins earlier in 
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the late luteal phase, resulting in a shortening in the cycle (19). In older pre-menopausal 
women, the menstrual cycle is irregular due to anovulation (20). 
Figure 2. Schematic picture of the menstrual cycle showing both hormonal changes and development of the 
follicle and endometrium. 
 
Attribution to Chris 73 / Wikimedia Commons [GFDL 1.3 (www.gnu.org/licenses/fdl-1.3.html) or CC-BY-SA-
3.0 (http://creativecommons.org/licenses/by-sa/3.0)], via Wikimedia Commons. 
2.3 OVARIAN RESERVE 
The ovarian reserve represents the ability to conceive based on the quality and quantity of the 
ovarian follicle pool, which is composed of the small resting oocytes inside the primordial 
follicles. The ovarian reserve diminishes with age: of the initial 6 - 7 million primordial 
follicles presenting in the ovaries at the fifth month of foetal life, only 400,000 – 600,000 will 
remain at menarche. There is an important difference in the starting follicle cohort among 
women (21). Approximately 400 of the original follicles will ovulate, and the vast majority 
will undergo atresia by apoptosis (22). When women reach the age of 50 -51, about 1000 
follicles remain, and the women reach menopause as a consequence. The median menopausal 
age in Sweden is 51 years (23). Several ovarian reserve tests have been used to evaluate 
ovarian reserve and fertility, but all of these tests and estimations remain proxies of the 
ovarian reserve. The most commonly-used tests include gonadotropins (FSH), AMH and the 
count of the antral follicles by ultrasound (AFC).  
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Figure 3. The decreasing follicle pool, increasing poor quality oocytes and its corresponding reproductive life 
events. 
 
2.4 ASSESSMENTS OF OVARIAN RESERVE 
Both clinical and biochemical markers are currently used to assess the female ovarian 
reserve. 
2.4.1 Menstrual cycle length 
The menstrual cycle changes over the course of the reproductive period. Research shows that 
the menstrual interval will shorten by two days between 20 and 40 years of age (18, 24). The 
length of the cycle has also been associated with fecundity. A cycle length of 30 - 31 days 
precedes the highest rate of fecundity (25). A study shows that live birth rates decrease for 
every menstrual length lower than 34 days in women undergoing IVF/ICSI treatment (26). 
Even though a shortening cycle length may indicate diminishing ovarian reserve, cycle length 
is not commonly used as an ovarian reserve test. 
2.4.2 Follicle-Stimulating Hormone (FSH) 
The pituitary gland secretes FSH, with the primary function of stimulating follicular growth. 
FSH levels are controlled by feedback mechanisms: the ovaries secrete oestrogen and 
regulatory peptides (Inhibin A and B) that control the amount of FSH secreted by the 
pituitary gland. When the oestrogen and inhibin levels are low, there is increased FSH 
secretion. In the menopausal transition, the FSH increases as fewer follicles are recruited 
every month, resulting in lower levels of oestrogen being secreted and a less efficient 
  13 
negative feedback mechanism (27). The opposite occurs when there are high concentrations 
of oestrogen and inhibin (28). Serum FSH is measured early in the follicular phase to 
evaluate the ovarian reserve, usually on menstrual cycle day -3 when oestrogen levels are 
normally low. Elevated FSH is a late sign of decreased ovarian reserve and menopausal 
initiation. 
2.4.3 Anti-Müllerian Hormone (AMH) 
Research showing that the ovaries express this glycoprotein began 30 years ago (29), and 
there has been growing interest in the use of AMH over the last decade. The production of 
AMH takes place in the granulosa cells (30). Granulosa cells in secondary, preantral and 
small antral follicles up to 6 mm of size express the highest amount of AMH (31).  
Figure 4. Comparison of AMH concentrations with non-growing follicles (NGF) population and with NGF 
recruitment. The red line illustrates log-unadjusted validated AMH, which peaks at 24.5 years. The blue line 
shows the decline of the NGF population, peaking at 18-22 weeks of gestation. The green line represents the 
number of NGFs recruited towards maturation, peaking at 14.2 years (14). 
 
 
 
Reprinted with the permission of PLoS One. Kelsey, T. W., P. Wright, S. M. Nelson, R. A. Anderson and W. 
H. B. Wallace (2011). “A Validated Model of Serum Anti-Mullerian Hormone from Conception to 
Menopause.” PLoS One 6(7). 
 
Initially, researchers hoped that the AMH test would be able to predict the length of women’s 
fertility period.  Normograms of AMH levels at different ages for both infertile and fertile 
patients have been created (32, 33). Bentzen et al, has demonstrated a 5.6% yearly decline of 
AMH (34). In another study by La Marca et al, fertile women demonstrated a median yearly 
AMH decline of about 0.16 µg/L (35). There is a peak of AMH concentration in serum at 
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24.4 years of age (36). Age-related changes in AMH levels occur much earlier than in any 
other ovarian marker, such as FSH and Inhibin B (37). Several long-term follow-up studies 
show that serum AMH is an accurate predictor of age at menopause (38-40). The serum 
concentration of AMH can be low 5 to 10 years prior to the onset of menopause. 
 Table 1. Studies of AMH as a predictor of ovarian aging and menopause in cohorts of fertile women. 
 Study design Number of 
women 
Age Follow-up time Results 
Tehrani et al 
2011 (41) 
Cohort study 1265 20-49yr 6 years with 3 
years interval        
 
Good correlation for 
prediction of 
menopause. 63 
women reached 
menopause. 
Broer et al 2011 
(42) 
Cohort study 257 21-46yr 11 years  Normogram, Model 
adequacy 90%. 48 
women reached 
menopause. 
Freeman et al 
2012 (43) 
Cohort study 401 35-48yr 14 years  If AMH < 0.2 µg/L, 
time to menopause 
was 6 yrs. 183 
women reached 
menopause. 
Tehrani et al 
2013 (39) 
Cohort study 1015 20-50yr 10 years Model adequacy 
92%. 277 women 
reached menopause. 
 
Clinical studies initially demonstrated that AMH was cycle-independent, displaying less 
intra-individual variation than any other current ovarian markers (44). Recently, an inter-
cyclic variation of AMH has been demonstrated (45). There are contradictory findings 
regarding the effect of exogenous sex-steroids or contraceptive treatment on AMH levels: 
some studies demonstrate no impact, while others show a tendency towards lower levels of 
AMH (46, 47). In the few studies published on the subject, there are discrepancies regarding 
AMH concentrations during pregnancy. One study demonstrated a decline of AMH (48), 
while another showed no significant difference in AMH levels during pregnancy (49). 
Pregnant women have an extra plasma volume of about 40 %, which might cause falsely low 
AMH concentrations.  
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Figure 5. Normal range of AMH in young adults and women based on a model presented by Kelsey et al 
(14). 
 
Reprinted with the permission of PLoS ONE. Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace 
WHB (2011). A Validated Model of Serum Anti-Müllerian Hormone from Conception to Menopause.  
AMH serum concentrations have shown clinical value in the context of IVF (50). In order to 
make ovarian stimulation well-tolerated and effective, it can be valuable to have previous 
knowledge of the woman’s ovarian reserve and her possible response to ovarian stimulation 
(51, 52). Assisted reproduction techniques aim to avoid poor response/cycle cancellation or 
overstimulation of the ovaries (OHSS). No studies demonstrate the ability of AMH to predict 
live births and oocyte quality (53). In fact, live births occur even when very low AMH values 
have been detected (54). Studies present varying results for using AMH levels to predict 
spontaneous pregnancy. One study suggests that AMH could predict fecundity in women 
aged 30-42 years (55). However, the results could not be replicated in another study with a 
younger population of women (56). 
2.4.4 Measurement of AMH  
Since 2002, a number of assays have been used for measuring AMH in human studies, 
including the ELISA KIT by Immunotech (IOT) and the Diagnostic System Lab assay (DSL 
assay). In 2010, the Beckman Coulter microplate assay was introduced, which is an 
enzymatically applied two-site immune assay with a more stable antibody (57). The assay 
uses anti-AMH antibodies to bind to AMH. After incubation and washing, substances are 
added that give a colour change based on enzymatic reaction. The last step is to detect the 
intensity of light by spectrophotometry. In assay analyses, it is standard practice to report the 
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inter-assay and intra-assay coefficient of variability (CV). The inter-assay CV expresses the 
plate-to-plate consistency, and the intra-assay CV describes the variation within each data set 
of one experiment. Each laboratory produces its own inter- and intra-assay CV. Two studies 
have shown the inter- and intra-assay to be smaller (< 5 %) with Beckman Coulter’s Gen II 
assay (58, 59). Beckman Coulter’s Gen II assay has the advantage of greater sensitivity, with 
values as low as 0.08 µg/L compared to the IOT assay. There are also no cross-reactivates 
between inhibin, FSH or LH (59). Unfortunately, there is no comparability between the 
different assays (60), and poor assay reproducibility has been demonstrated (58). Gen II 
AMH concentrations were about 20 % lower compared to DSL (58). Pre-dilatation, storage at 
-20°C for five days or incubation at room temperature for seven days increased the AMH 
concentrations (58). In July 2013, Beckman Coulter released a field safety notice that AMH 
samples could be reported lower than expected. Differences of 70 % were observed for 
samples tested within 1-2 hours. Research has demonstrated that freshly-drawn or freshly-
frozen samples have a higher risk of complement interference (61). In the same laboratory, 
the inter- and intra-assay variability has been small (58), but between laboratories, there has 
been a wide range of values (62).   
2.4.5 Antral follicle counts (AFC) 
It is not possible to estimate the number of primordial follicles in the ovaries, which 
constitutes the real reserve pool of eggs. However, the antral follicles growing at the 
beginning of the menstrual cycle can be imaged by ultrasound. Vaginal ultrasound can 
visualize small follicles of 1-2mm. Studies have shown that counting the antral follicles of 2-
10 mm reflects the number of primordial follicles (63, 64). AFC can also predict oocyte yield 
(64), poor response to hormone stimulation (65) and live birth rates in ART treatments (66). 
Median AFC decreases by 0.4 for every year of increasing age (67). Research shows a 
correlation between AMH and AFC (68) 
Figure 6. Vaginal ultrasonography illustrating an ovary with numerous antral follicles. 
  Antral follicles 
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2.5 ASSISTED REPRODUCTIVE TECHNIQUE (ART) 
A large proportion of the women who participated in the studies of this thesis have undergone 
fertility treatments by assisted reproductive technologies (ART). In Sweden, conventional In 
Vitro Fertilization Treatment (IVF) and Intracytoplasmic Sperm Injection (ICSI) are widely 
available within the tax-financed health care system. The aim of IVF/ICSI treatments is to 
obtain several oocytes to fertilize in the laboratory. The embryos obtained are cultured for 
several days and categorized according to their morphological aspects. Usually, one embryo 
is transferred into the womb during the treatment cycle, and supernumerary embryos can be 
frozen for later treatments. The recovery of several oocytes is achieved by the administration 
of supraphysiological doses of gonadotropins (FSH) to stimulate the development of several 
ovarian follicles during the same cycle. Gonadotropins can only recruit follicles that have 
reached the mature state of FSH dependency. Subcutaneous injections with individualized 
recombinant FSH (rFSH) or urinary-derived gonadotropin (hMG) are given for 10 ± 2 days. 
At day 5-7 of injections, the ovarian response is monitored by ultrasound, often in 
combination with serum oestradiol. The growing follicles produce a large amount of 
oestradiol, which can cause a premature LH surge through the negative feedback mechanism. 
To prevent potentially premature ovulation, there are two different treatment protocols: one 
uses down-regulation with GnRH agonists, and the other uses GnRH antagonists. 
In the GnRH antagonist protocol, the FSH injections are started on cycle day 2-3, and a 
GnRH antagonist is added when the largest follicle reaches 10-12 mm or on a fixed day (day 
5-6 of FSH stimulation) to be continued thereafter until ovulation. 
Figure 7. Schematic illustration of the GnRH antagonist protocol and the long down-regulation protocol with 
GnRH agonist. 
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When using the long down-regulation of the pituitary gland, a GnRH agonist is usually 
started a week before expected menstruation, cycle day (cd) 21, and is continued until 
ovulation. The goal behind this process is exhaustion of the pituitary gland, which shuts off 
gonadotropin secretion. FSH injections are added after 2-3 weeks of GnRH agonist use.  
Ovulation is induced when three or more follicles reach the size of 17 mm, as measured by 
transvaginal ultrasound. The LH surge is stimulated by an injection of hCG. Oocyte pick-up 
(OPU) is undertaken by transvaginal ultrasound puncture 36-37 hours after the hCG 
injection. In the conventional IVF setting, the oocytes and spermatozoa are mixed, and a 
natural selection of fertilization occurs; in ICSI, a single sperm is injected into the oocyte. 
Embryo transfer is performed after 2-5 days of embryo culture. All women receive luteal 
phase support with progesterone.  
The clinical outcome of ART treatment can be reported as the clinical pregnancy rate (CPR) 
or the live birth rate (LBR) per started cycle or per OPU. This will give lower result rates 
compared to CPR or LBR/embryotransfer, as there are always some treatment cancellations. 
The clinical pregnancy rate or LBR per embryo transfer are usually reported as well. In the 
yearly ART surveillance from the United States, the cancellation rate was about 15 % in 
2011, the LBR/started cycle was 31 % and the LBR/Embryo transfer was 37 % (69). The live 
birth rate in Sweden per ET for fresh cycles is between 25-27 % and about 20 % for frozen 
cycles (70). 
2.6 OVARIAN CYSTS 
Ovarian cysts are common among premenopausal women. A cyst is commonly defined as a 
fluid-containing structure of more than 30 mm. In young women, the prevalence of ovarian 
cysts is approximately 7 % (71, 72). The lifetime risk of ovarian cancer is one in 70 women, 
but this number increases with age and with a family history of ovarian cancer (73, 74). There 
are several different histopathologic types of benign ovarian cysts: follicular/functional cysts, 
corpus luteum cysts, endometriomas, cystadenomas (serous and mucinous) and teratomas. 
Some can be diagnosed easily through pattern recognition with ultrasound (75). Several 
guidelines from western countries attempt to describe when cyst surgery is necessary for 
women of pre-menopausal age (76-79). Most guidelines recommend diagnosis with 
ultrasound to discriminate between malignant and benign cysts. The International Ovarian 
Tumour Analyses (IOTA) group has developed simple ultrasound rules to help the clinicians 
differentiate potential malignant cysts form benign (80, 81). The guidelines recommend 
Magnetic Resonance Imaging (MRI) as a secondary step when the adnexal mass is unclear. 
Both the American College of Obstetricians and Gynecologists (ACOG) and the Royal 
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College of Obstetricians and Gynaecologists (RCOG) recommend expectant management of 
benign ovarian cysts if they are asymptomatic and smaller than seven centimetres. If the cysts 
are smaller than five centimetres, no follow up is needed (76, 79), and if surgery is needed, 
laparoscopy is the preferred choice. A recent review article by Legendre et al concludes that, 
with dermoid cysts, a “wait-and-see” attitude is probably acceptable if the cyst is 
asymptomatic and 4-6 cm (82). The same article also recommends expectant management for 
endometriomas. 
Figure 8. Trends in ovarian surgery in Sweden 2005-2012. From the National Board of Health and Welfare (83). 
 
 
2.6.1 Impacts of ovarian cyst surgery on ovarian reserve 
Several studies indicate that ovarian cyst surgery may induce a reduction of serum AMH 
concentrations (84) (85-87), thus suggesting a possible negative impact of cyst enucleation 
surgery. This effect might be due to unavoidable surgical damage to the normal ovarian tissue 
surrounding the cyst. Two systematic reviews have looked at heterogeneous studies published 
on the impact of ovarian surgery on ovarian reserve (88, 89). Both concluded that there is an 
association between ovarian surgery and AMH decline. Table 2 presents the available studies 
of AMH changes following ovarian cyst enucleation. Enucleation involves identifying the 
cyst wall and removing it from the ovarian cortex. In order to make results generalizable, it is 
important to define a proper and comparable study population. Studies presented in Table 2 
only include women who have undergone cyst enucleation. No apparent removal of ovarian 
tissue was reported; however, they are heterogeneous, as they included women of different 
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age groups from a mean age of 28 years (87, 90, 91) to a mean age of 33 years (86, 92, 93). 
All of the studies used the same operation technique, the stripping method for cyst 
enucleation. Additionally, two of the studies included a control group that had a different 
operation; unilateral oophorectomy or three-step approach (94, 95). There were differences in 
the number of surgeons performing the operations. To reduce the risk of performance bias, 
two of the studies had two surgeons who performed all of the ovarian surgeries (96, 97). The 
studies also used different AMH assay kits, and as reported earlier, they are not comparable. 
Only a few of the studies reported low intra- and inter-assay variability estimated as 
coefficient of variability (CV) (86, 90, 91). Median AMH levels were reported by a few 
studies (85, 86), while the remaining studies only reported mean values that could be 
incorrect if the distribution was not normal or if they had extreme values that affected the 
results. In the available studies, the identified predictive factors of a decline in AMH levels 
included surgery for endometriomas, especially if bilateral (97). The prospective cohort study 
by Chang et al should be highlighted due to the high quality of its design. In this study, all 
AMH samples were analysed in the same assay after freezing the samples, and the intra- and 
inter-assay variability was low (86). A control group of non-endometriomas was also 
included. The most recent prospective studies by Kwon et al (97) and Uncu et al (96) tried to 
eliminate confounders using extensive exclusion criteria, and both studies had a control group 
with either women with other benign cysts or women without ovarian cysts. A very limited 
number of surgeons performed all ovarian surgeries, which minimized the risk of 
performance bias.  
 
Table 2. Available studies on changes in ovarian reserve following ovarian surgery, estimated as changes in 
serum AMH concentrations. All but one of the studies (Tsolakidis et al, 2010) (94) were prospective cohort 
studies. The studies have used different AMH assays: Beckman Coulter’s Gen II assay, the older ELISA KIT by 
Immunotech (IOT) and the Diagnostic System Lab assay (DSL assay). All of the studies used the stripping 
technique for removing the ovarian cysts. 
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Study Type of cyst 
investigated 
No. of cases 
(unilateral/bil
ateral cysts) 
Mean 
diameter 
(mm) 
Presurgery 
AMH 
Postsurgery 
AMH 
Time of 
follow-up 
Change et al 
2010 (87) 
Endometrioma 
(n=13)   
Dermoid (n=6) 
Other (1) 
19 (13/6) NR 2.23 (1.35-3.1) 0.8 (0.7-1.6) 3 months 
Biacchiardi et al 
2010 (94) 
Endometrioma 43 (33/10) 37 ±11 3.0 ± 0.4 1.3 ± 0.4a 9 months 
Tsolakidis et al 
2010 (95) 
Endometrioma 10 (7/3) ≥30 3.9 ± 0.4 2.9 ± 0.2a 6 months 
Ercan et al 2010 
(91) 
Endometrioma 47 (33/14) ≥45 1.6 ± 1.1 1.4 ± 1.2 1 month 
Iwase et al 2010 
(86) 
 
Endometrioma 
(n=29)   
Dermoid (n=18) 
29 (16/13)      
NR 
NR 3.0 (0.5-12.1) 
3.9 (0.1-10.1) 
2.2 (0.1-7.2)a 
3.3 (0.1-9.1)a 
1 month 
Lee et al 2011 
(96) 
 
Endometrioma 13 (13/0) 40 ± 18 4.7 ± 2.5 3.3 ±2.1a 3 months 
Hirokawa et al 
2011 (93) 
Endometrioma 38 (10/28) 64 ±22 3.9 ± 2.5 2.1 ± 1.6a 1 month 
Kitajima et al 
2011 (85) 
Endometrioma 
(n=19)    
Dermoid (n=13) 
19 (19/0) 
NR 
67 ± 19 
68 ± 21 
4.3 ± 3.0 
4.0 ± 2.2 
- 25% ± 29%a   
-3%  ±  34.4% 
3 months 
 
Ercan et al 2011 
(99) 
Endometrioma 36 (36/0) 25 ± 23 2.0 ± 0.4 2.0 ± 0.6 3 months 
Hwu et al 2011 
(100) 
Endometrioma 31 (31/0) ≥30 3.9 ± 0.4 2.0 ± 0.2 3 months 
Celik et al 2012 
(88) 
 
Endometrioma 65 (46/19) 59 ± 21 1.8 ± 1.7 0.7 ± 0.8a 6 months 
Urman et al 
(2013) (101) 
Endometrioma 25 (25/0) 51±15  24% reduction 
from pre-
operative levels 
6 months 
Uncu et al 2013 
(97) 
Endometrioma 30 (15/15) 43 (36-52) 2.8 ± 2.2 1.8 ± 1.3a 6 months 
Alborzi et al 
2013 (92) 
Endometrioma 193 
(121/72) 
NR 3.9 ± 3.6 1.8 ± 7.8a 9 months 
Sugita et al 2013 
(102) 
Endometrioma 39 (22/17) 80 ± 30 3.6 ± 2.1 2.1 ± 0.9a 12 months 
Kwon et al 2014 
(98) 
 
Endometrioma 
(n=68)   
Dermoid (n=15) 
Other benign 
cysts (n=17) 
68 (42/26) 
32(24/8) 
63 ±25 
60 ± 23 
4.97 ± 2.83 
5.03 ± 3.07  
3.33 ± 2.08a  
3.22 ± 2.09a 
3 months 
ap value < 0.05, NR: Non-Reported 
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2.6.2 Patients’ fertility-related information prior to ovarian surgery 
In many countries, women sign a consent form prior to surgery, but this is not the case in 
Nordic countries. International data suggests that even though patients sign a formal 
consent prior to surgery, they may not fully understand the content (102). Some people 
argue that information to patients will be sparse without a signed consent; in Sweden, 
however, a new patient law has just been implemented, regulating and extending the 
information duty towards patients and expanding the patients’ participation in their own 
care. ACOG recommends patient-centred interviewing and caring communication skills, 
especially when informing of evidence-based specific risks and benefits of surgery (103). 
Only a few guidelines comment on the need for fertility information prior to surgery. The 
guidelines from the RCOG regarding complex gynaecological surgery state that “the 
outcomes of the proposed surgery should be discussed, including what loss of function is 
acceptable – in particular the possible loss of fertility” (104). The European Society of 
Human Reproduction and Embryology’s (ESHRE) guidelines for endometriosis 
recommend that “clinicians should provide counselling to women with endometriomas 
regarding the risks of reduced ovarian function after surgery and the possible loss of the 
ovary”(105).  
2.6.3 Effects of unilateral oophorectomy  
A British cohort study of women born in 1946, who have been followed with yearly 
questionnaires from the age of 47 years, showed that women undergoing unilateral 
oophorectomy (UO) seem to reach perimenopause one year earlier than matched controls 
(106). Perimenopause was defined as irregular periods for 12 months or no period for three to 
12 months. A recent study that used self-reported age at menopause has confirmed that 
women with one ovary reached menopause one year earlier than controls (107). As 
demonstrated in Table 3, the abrupt reduction of the number of ovarian follicles by unilateral 
oophorectomy may have a distinctive impact at different ages (108). 
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Table 3. Studies published on the effect of unilateral oophorectomy on age at menopause.  
 Study 
design 
Total 
group 
(n) 
UO (n) Total group, Mean age at 
menopause 
UO, Mean age at 
menopause 
P-value Data 
collection 
Cramer 
et al 1995 
(109) 
Case 
control 
688 10  OR for earlier 
menopause 
4.3(0.90-20.44) 
NS Questionnaire 
Hardy et 
al 1999 
(106) 
Cohort 1166 21 48 (perimenopause) 47 
(perimenopause) 
0.02 Questionnaire 
Yasui et 
al 2012 
(110) 
Cohort 24152 827 52.1 (95% CI 52.0-52.2) 50.9 (95 % CI 
50.7-51.6) 
<0.0001 Questionnaire 
Thomas-
Teinturer 
et al 2013 
(111) 
Cohort 706 40 49 years (95 % CI: 48–
50)  
42 years (95 % 
CI: 40–46) 
NR Questionnaire 
of cancer 
survivors 
Bjelland 
et al 2014 
(107) 
Cohort 23580 1055 50.6 (95% CI 50.5-50.7) 49.8 (95% CI 
49.4-50.3) 
<0.001 Questionnaire 
UO: Unilateral Oophorectomy, OR: Odds Ratio, CI: Confidence Interval 
 
Previous data on women with only one ovary who have undergone ART treatments (IVF) 
have reported similar pregnancy rates compared to women with two ovaries; however, the 
women with one ovary needed a higher FSH dose for stimulation, and fewer oocytes were 
retrieved at OPU (108, 112-116). Remarkably, in one previous study, an increased pregnancy 
rate was found after IVF/ICSI treatment in women with UO when compared to controls 
(117). Most of the previous studies were small in size, and multiple embryos were transferred 
(108, 112, 113, 116, 117). 
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Table 4. Studies on women with a history of unilateral oophorectomy (UO) who underwent IVF/ICSI treatment 
(Exposed; Exp) compared to controls. In most of the studies, multiple embryos were transferred. 
 
Study Wome
n with 
UO 
(Cycles
, n) 
Controls 
(Cycles, 
n) 
Mean 
Embryo
s 
transfer
red  
Exp vs 
controls 
Main Outcome Clinical 
Pregnancy rate 
(CPR),             
Live birth rate 
(LBR),                     
Exp vs controls 
Definition of 
pregnancy 
Alper et 
al 1985 
(118) 
14 
 
14 
 
2.2 vs 
2.4 NS 
FSH dose+ oocyte 
yield NS 
PR: 14.3% vs 
28.6 %. NS 
NR 
Dodds et 
al 1987 
(119) 
16 (20) 18 (34) 1.7 vs 
2.7   S 
FSH dose+ oocyte 
yield NS 
PR/ET 14 % vs 
36 %. NS 
NR 
Lam et al 
1987 
(120) 
34 (60) 335 
(559) 
3 vs 3  ⬇ Oocytes in 
women with UO. S. 
CPR/OPU 9.7 % 
vs 15.6 %. NS 
Clinical 
pregnancy 
verified by 
ultrasound  
Bouttevil
le et al 
1987 
(121) 
86 
(162) 
415 
(788) 
2.3 vs 3 
S. 
 
⬇ Oocytes in women 
with UO. S. 
CPR/ET 23.9 % 
vs 24.4 %. NS 
Clinical 
pregnancy 
verified by 
ultrasound 
Dodson 
et al 1987 
(122) 
(23) (125) 3.9 vs 
4.5 NS 
FSH dose+ oocyte 
yield NS 
PR: 8.3 % vs 
12.9 %. NS 
NR 
Khalifa 
et al 1992 
(123) 
(162) (1110) 2.4 vs 
3.0 NS 
 ⬇	  Oocytes in 
women with UO. S. 
CPR: 13 % vs 
18 %. NS 
 
Clinical 
pregnancy 
verified by 
ultrasound 
Penzias 
et al 1993 
(124) 
7 84 3.6 vs 
4.0 NS 
FSH dose+ oocyte 
yield NS 
NR NR 
Nargund 
et al 1995 
(125) 
17 (25) 27 (33) 1.9 vs 
2.5 NS 
⬇	  Oocytes in women 
with UO. S. 
CPR: 
Significantly 
lower in women 
with UO 
Clinical 
pregnancy 
verified by 
ultrasound 
Lass et al 
1997 
(113) 
58 (73) 881 
(988) 
2 vs 2 
NS 
⬆ FSH dos                    ⬇	  Oocytes in women 
with UO. S. 
CPR/OPU 25.8 
% vs 27.1  % NS 
LBR NS 
Clinical 
pregnancy 
verified by 
ultrasound 
Levitas 
et al 2000 
(117) 
10 (20) 47 (60) 3 vs 2.9 FSH dose+ oocyte 
yield NS 
CPR: 52.9% vs 
20.8%. S 
Clinical 
pregnancy 
verified by 
ultrasound 
Levi et al 
2003 
(112) 
46  (46) 123 
(123) 
2.1 vs 
3.3 
⬆ FSH dos                    ⬇	  Oocytes in women 
with UO. S. 
CPR: 8.7 % vs 
19.5 %. NS 
Clinical 
pregnancy 
verified by 
ultrasound 
Al-
Hasani et 
al 2003 
(116) 
24 (3) 109 
(191) 
2.6 vs 3 ⬆ FSH dos                    ⬇	  Oocytes in women 
with UO. S. 
CPR: 22.2 % vs 
17.2 %.NS 
Clinical 
pregnancy 
verified by 
ultrasound 
Hendrick
s et al 
2010 
(115) 
18 (22) 44 2.6 vs 
2.8 
⬆ FSH dos                    ⬇	  Oocytes in women 
with UO. S. 
CPR: 31.8 % vs 
43.2 %. NS 
Clinical 
pregnancy 
verified by 
ultrasound 
Khan et 
al 2014 
(114) 
51 102 NR ⬇	  Oocytes in women 
with UO. S. 
CPR: 33.3 % vs 
52.9 %. S          
LBR 31.1 % vs 
46.8 % NS 
Clinical 
pregnancy 
verified by 
ultrasound 
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CPR= Clinical Pregnancy Rate, FSH= Follicle Stimulating Hormone, LBR= Live Birth Rate, NR= Not 
Reported, NS=Not Significant, OPU= Ovum pick-up, PR= Pregnancy Rate, S= Significant p <0.05, UO= 
Unilateral Oophorectomy 
 
Researchers question whether reproductive aging involves a pre-determined decline of 
remaining ovarian follicles or an age-dependent process. In the pre-determined model, the 
unilateral oophorectomy induces a reduction of the follicle pool by half, but there would still 
be an equivalent decline in follicles. Therefore, a unilateral oophorectomy would have 
varying effects depending on age; a unilateral oophorectomy at an earlier age would lead to 
earlier menopause, as there is an equivalent decline the entire time in this model. In the 
alternative age-dependent model, a decline of half the rate of a non-operated woman would 
occur after unilateral oophorectomy; therefore, the age of the unilateral oophorectomy would 
have less impact on menopausal age (126). This alternative model aligns more with the 
previously-reported studies showing menopause only one year earlier following unilateral 
oophorectomy (106, 109-111). 
 
Figure 9. An illustration of the two theories regarding the effects of a unilateral oophorectomy on the age of 
menopause onset. The green line represents the pre-determined model, and the red line shows the alternative 
age-dependent model for unilateral oophorectomy at ages 10, 20 or 35 (126). 
 
Reprinted with permission from PLoS One. Wilkosz, P., G. D. Greggains, T. G. Tanbo and P. Fedorcsak (2014). 
"Female reproductive decline is determined by remaining ovarian reserve and age." PLoS One 9(10): e108343 
 
2.7 ASPECTS OF INFERTILITY IN WOMEN 
As a consequence of diminished ovarian reserve due to advanced age, ovarian surgery or 
cancer treatments, a woman might remain childless or have a smaller family than desired, a 
phenomenon known as primary or secondary infertility. Infertility is a global problem 
affecting women in developing countries more than women in developed nations because of 
 26 
infectious diseases and lack of medical reproductive treatments (127). In 2010, there were 
approximately 48.5 million couples affected by infertility (127). 
Figure 10. Worldwide prevalence of primary infertility among women seeking a child in 2010 (127). 
 
Reprinted with permission from PLoS Med. Mascarenhas, M. N., S. R. Flaxman, T. Boerma, S. Vanderpoel 
and G. A. Stevens (2012). "National, regional, and global trends in infertility prevalence since 1990: a 
systematic analysis of 277 health surveys." PLoS Med 9(12): e1001356. 
 Infertility can have cultural impacts for women in different societies. It can lead to both 
social and psychological consequences, such as divorce, social stigma and isolation (128, 
129). One consequence of infertility is feeling a loss of control over one’s own life (130). In 
social contexts, women have to deal with feelings of being left out and/or jealous of women 
who are pregnant (130). Women seem to use coping strategies more than men, including 
seeking social support, avoiding contact with people that remind her of her infertility 
(escape/avoidance) and accepting responsibility (believing that she is responsible for the 
infertility) (131). Infertile women have a higher risk of depression and diabetes (132). In one 
study, women reported that infertility and IVF treatment was one of the most stressful events 
of their lives (130). Information and communication are the most important variables in 
patient-centred care for infertile women (133). Guidelines recommend providing fertility-
related information prior to medical treatments that can affect reproduction, such as ovarian 
surgery or cancer treatments (104, 105). Armuand et al report that less than half of women 
undergoing cancer treatment receive fertility-related information beforehand, and only 14 % 
are informed of fertility preservation options (134).  
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3 RATIONALE 
In Sweden, nearly 3300 ovarian cyst surgeries are performed in women of reproductive age 
per year. More ovarian surgeries are performed on women over 30 years of age compared to 
younger women. The risk of having a benign cyst before attempting pregnancy has increased 
because women today are delaying childbearing. Therefore, these women have a greater risk 
of experiencing ovarian surgery, a potential threat to their fertility. Even though clinical 
guidelines recommend a conservative and more expectant attitude towards asymptomatic 
benign cysts < 7cm, there has been a slow increase in the annual rates of ovarian surgeries in 
Sweden. Prior to making a decision, patients require adequate information regarding the risks 
of ovarian surgery, its complications and potential effects on fertility.  
Ovarian surgery for endometriomas has previously been shown to associate with a reduction 
of AMH up to one year after surgery. Further research is needed to study the long-term 
effects of ovarian surgery for endometriomas in the women’s ovarian reserve, as well as for 
the various non-endometriotic cysts presenting in young women. Such research also needs to 
investigate the final effects of ovarian surgery on direct estimations of fertility, such as 
pregnancy rates. International guidelines state that reproduction should always be discussed 
before ovarian surgery, yet there are no published studies regarding the extent to which this 
information is provided. Also lacking from the literature are studies regarding women’s 
informational needs prior to ovarian surgery.  
This thesis aims to contribute to the knowledge regarding the effects of ovarian surgery on 
ovarian reserve and female fertility so that healthcare professionals might provide improved 
information and counselling adapted to the individual patient. After receiving such 
individualized information, women of today can make informed decisions with regard to their 
fertility issues and surgery. 
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4 AIMS  
The overall aim of this thesis was to investigate short- and long-term effects of ovarian 
surgery on the ovarian reserve of women of reproductive age, their reproductive outcomes, 
and their perceptions of information received about fertility and their ovarian surgery.  
 
 Specific aims 
Paper I To investigate patients’ perceptions of fertility-related information received and 
fertility distress prior to ovarian cyst surgery.  
Paper II To prospectively investigate the effects of ovarian cyst surgery for several cyst 
types on women’s ovarian reserve, estimated as serum AMH concentrations, 
three and six months following ovarian surgery.  
Paper III To prospectively examine the impact of changes in serum AMH following 
ovarian cyst surgery on reproductive outcomes in women attempting to achieve 
pregnancy within a two-year follow-up period.  
Paper IV   To investigate if women with a history of unilateral oophorectomy treated by 
IVF/ICSI would have a reduced likelihood of achieving clinical pregnancy 
compared to women with intact ovaries.  
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5 METHODS 
5.1 STUDY DESIGN 
This thesis includes two studies reported in four papers (Table 5). The studies have different 
methodological designs. Study I resulted in three papers: paper I had a cross-sectional design, 
while papers II-III involved a prospective cohort design with a follow-up cut-off time of six 
and 24 months, respectively. The study population in study I (papers I-III) was enrolled at 
Södersjukhuset prior to ovarian surgery for possible benign ovarian cyst. Study IV is a 
multicentre cohort study based on clinical registry data from three large reproductive 
medicine centres. The clinics that participated are Carl von Linné Clinic Uppsala, 
Reproduction Centre Uppsala University Hospital and Reproductive Medicine Karolinska 
University Hospital. The women included in the study underwent their IVF/ICSI treatments 
between January 10, 2003 and January 13, 2014. 
 
Table 5. Overview of the general design of the project. 
 
Study Design Data collection Participants Paper 
Analysis 
1 Cross sectional   
 
Study-specific 
measures from 
questionnaire, 
FPI 
 
106 women answered the 
questionnaire when they 
were planned for ovarian 
cyst surgery. 
 
I Logistic regression 
1 Prospective cohort 
Inclusion from 
2011 to 2012; 
follow-up 
completed Sept 
2012.  
 
Clinical data 
Ultrasonography 
of AFC      
Blood samples 
for serum AMH 
Clinical prospective 
cohort of 75 women who 
underwent ovarian cyst 
surgery. 3- and 6-month 
follow-up. 
 
II Shapiro-Wilks, 
Wilcoxon signed 
rank test, χ2test, 
Kendall’s r,  
Logistic regression 
 
1 Prospective cohort 
Inclusion from 
2011to 2012; 
follow-up 
completed March 
2014.  
 
Clinical data 
Ultrasonography 
of AFC      
Blood samples 
for serum AMH 
Questionnaire at 
24 month 
follow-up 
 
2-year follow-up of the 
clinical cohort. 
66 women attended 24-
month follow-up visit. 
III Wilcoxon signed 
rank, Mann-
Whitney U test 
Kendall’s r,  
 
2 Multicentre cohort 
study. Exposed 
cohort with 
unilateral 
oophorectomy and 
unexposed 
controls were 
treated with 
IVF/ICSI between 
2003 and 2014. 
 
Clinical registry Data on IVF/ICSI 
treatments were collected 
at three large fertility 
clinics in Sweden.         
76 exposed women with 
previous unilateral 
oophorectomy and 12879 
unexposed control 
women. 
 
IV GEE model 
AFC: Antral Follicle Counts, AMH: Anti-Müllerian Hormone, FPI: Fertility Problem Inventory, GEE: 
Generalized Estimated Equation 
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5.2 STUDY SUBJECTS 
5.2.1 Study I (Papers I- III) 
The inclusion period of study I (papers I-III) started in March 2011, and the last patient was 
included in March 2012. Eligible were all women of reproductive age (18-44 years) planning 
to have surgery for ovarian cysts at the Department of Obstetrics and Gynecology in 
Södersjukhuset, Sweden. Indications for surgery included clinical symptoms, such as pain, 
pressure or fear of malignancy. Exclusion criteria were not being able to understand or write 
the Swedish language. 
The women were invited to participate in the study at the pre-surgery consultation with a 
gynaecologist, usually the day before surgery. The women received both written and oral 
information about the study and the current lack of knowledge on the impact of ovarian cyst 
surgery on remaining ovarian function. A total of 167 women were scheduled for ovarian 
cyst surgery during the study period at the clinic. 20 women declined to participate, and 35 
women were never asked to participate due to administrative failure.  
5.2.1.1 Paper I 
Six women did not complete the questionnaire in the cross-sectional design, which resulted in 
a response rate of 80 % (N = 106). 
5.2.1.2 Paper II 
Before surgery, participants in study I were offered the opportunity to participate in a 
prospective follow-up study to investigate the ovarian reserve through ultrasound and 
laboratory methods at three and six months. Of the 112 recruited women, 37 were excluded 
due to pregnancy, malignancy or because only fenestration was done at surgery and some 
were lost to follow up  (Figure 11). Of the 75 women participating, 54 women attended both 
the 3- and 6-month follow-up visits. 62 women attended the three-month follow up, and 67 
women attended the six-month follow up.  
5.2.1.3 Paper III 
In this prospective follow-up study, we invited all 75 participants from paper II plus ten 
women who underwent a cyst fenestration to participate in a two-year follow up. Two women 
were excluded, one due to malignancy and one due to hysterectomy. Of the 83 eligible 
women, 66 completed the two-year questionnaire, and 63 had a serum AMH test.   
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Figure 11. Flow chart of inclusion and participants in study I (papers I-III). 
 
 
 
 
5.2.2 Study II (paper IV) 
Data on women undergoing IVF/ICSI treatment were collected from the clinical registry at 
three large reproductive clinics in Sweden (Carl von Linné Clinic, Reproductive Medicine 
Karolinska University Hospital and Reproductive Centre Uppsala University Hospital). 
Women were excluded if they underwent IVF/ICSI treatment with donor gametes or if the 
treatment included preimplantation genetic diagnosis (PGD). The study period was defined as 
January 10, 2003 until January 13, 2014. The exposed cohort consisted of 76 women with a 
Study population n=167	  
Paper I 
Exluded due to; 
 did not complete 
questionnaire n=6	  
Paper I  
Included n= 106 
Paper II  
Excluded due to; 
Malignant cyst n=5 
Pregnancy n=12 
No follow up n=10 
Fenestration n =10	  
Paper II 
Included n=75	  
Attended  
3-month visit n=62	  
Attended  
6-month visit n=67	  
Paper III 
 Excluded due to; 
Malignant cyst n=6 
Pregnancy n=12 
No follow up n=10 
Hysterectomy n=1 
Lost to follow up 2yr n =17	  
Paper III 
Included n=66 
 Serum AMH analysed 
n=63 
Study sample n=112 
 
Not approached    
n= 35 
 Declined 
participation n=20 
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previous unilateral oophorectomy (UO). The unexposed control group consisted of 12879 
women with intact ovaries who underwent treatment with IVF/ICSI during the same study 
period at the three centres. Patients were included regardless of duration or cause of 
infertility. At two of the public clinics, there is an age limit of 40 years for women 
undergoing IVF/ICSI treatment: Reproduction Centre Uppsala University Hospital and 
Reproductive Medicine Karolinska University Hospital. Only sibling treatments with frozen 
embryos are allowed at an older age on a self-paying basis. Carl von Linné clinic is a private 
clinic that treats women up to 43 years of age. As a result, there was a difference in mean age 
between the centres. 
 
Table 6. Participants’ age by ART-centre and number of treatment included/centre in study II. 
 Total Carl von Linné 
Clinic 
Reproduction Centre, 
Uppsala University 
Hospital 
Reproductive 
Medicine, Karolinska 
University Hospital 
IVF/ICSI treatments 
in exposed women 
with UO (n)  
139 95 25 19 
IVF/ICSI treatments 
in control women (n) 
22477 11777 4269 6431 
Mean age (SD) 34.1(4.4) 35.1 (4.4) 33.4 (3.9) 32.6 (4.2) 
IVF: In Vitro Fertilization, ICSI: Intracytoplasmic Sperm Injection, SD: Standard Deviation, UO: Unilateral 
Oophorectomy 
 
5.3 EXPOSURE 
5.3.1 Ovarian cyst surgery (papers II and III) 
All women who participated in study I were included when planning for ovarian surgery, and 
all participants in studies II-III had ovarian cyst surgery either by laparoscopy or laparotomy. 
All surgical procedures were performed under general anaesthesia by an experienced 
gynaecologist. Laparoscopic surgery was performed with a 5-mm trocar with endoscope 
through an umbilical incision. Additionally, two to three 5-mm trocars were inserted 
suprapubically. The cyst cleavage plane was identified and traction with atraumatic forceps 
was used when there were no signs of malignancy. Sharp dissection with scissors was used to 
remove the adherent part of the cyst from the ovarian parenchyma. Haemostasis with bipolar 
electro-coagulation was applied with care, aiming to avoid damage to the normal adjacent 
ovarian tissue. The cysts were removed using an endobag and a 10-mm trocar. Adhesions or 
  33 
endometriosis in the peritoneum were always removed. Adhesion prevention products were 
used in most cases (Hyalobarrier®). Sometimes, a laparotomy was indicated by a large cyst 
size; then, a transverse Pfannenstiel incision was performed. Unilateral oophorectomies or 
ovarian resection were performed when macroscopical absence of any normal ovarian 
parenchyma without a cleavage plane was found during the surgery.  
5.3.2 Unilateral oophorectomy study II (paper IV) 
Exposed women in the study had a previous unilateral oophorectomy. The clinical registries 
provided no detailed information regarding the reasons for surgery. 
5.4  EVALUATED PARAMETERS  
5.4.1 Questionnaire study I (paper I) 
All women participating in study I completed a questionnaire, usually the day before surgery. 
The questionnaire included socio-demographic and reproductive variables. The questions had 
been used in previous studies (134, 135). Study-specific questions focused on education, 
household composition, pregnancy, parity, previous or ongoing hormone medication and 
prior infertility problems. One study-specific item assessed reproductive desire, asking 
participants to report their desire for children or additional children (Yes, No). Present 
infertility problems were assessed with a Yes or No question (including not having tried to 
conceive and lack of male partner). Fertility treatments were assessed by a question regarding 
specific treatment (insemination, ovulation induction with clomiphene citrate, IVF or oocyte 
donation). Fertility distress was defined as worry about future fertility and assessed with a 
visual analogue scale (VAS, endpoints 0=not at all worried and 10=very worried). 
Four different questions assessed perceptions of fertility-related information. The questions 
were adapted from a recent study (134) and included the following: 1) “Did you discuss the 
impact of the planned surgery on your fertility with the gynaecologist?” (Yes, No, Don’t 
remember), 2) “Briefly describe what you learned about your surgery and the potential 
impact of surgery on fertility” (open-response format), 3) “How satisfied are you with the 
received information regarding the potential impact of surgery on fertility?” (VAS scale, with 
endpoints 0=not at all satisfied and 10=very satisfied) and 4) “If you didn’t receive any 
information about the impact of surgery on fertility, what information would you have wished 
to receive?” (open response format). 
The Fertility Problem Inventory (FPI) (136) was used to assess distress related to the 
importance of parenthood using two subscales: 1) Need for parenthood (10 items) assessing 
the degree to which parenthood is perceived as an essential goal in life and 2) Rejection of a 
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child-free lifestyle (8 items) assessing negative views of a child-free lifestyle or status quo 
and future happiness being dependent on having a child. A six-point Likert scale ranging from 
“strongly disagree” to “strongly agree” were used for the responses. The FPI was initially 
developed for infertile patients; therefore, an additional response option – not relevant – was 
added (134). Women who provided ratings for at least half of the sub-scale items had their 
missing values and “non-relevant” responses replaced with the means of their individual 
ratings for those sub-scores. The FPI has shown high validity and reliability (136, 137). 
5.4.2 Questionnaire (paper III) 
At the two-year visit, the women answered a questionnaire similar to the presurgery 
questionnaire, including questions about reproductive desire, present infertility problems and 
fertility distress. Specific questions about reproductive outcomes since surgery were also 
added. 
5.4.3 AMH measurement (papers II-III) 
In study I, blood samples were drawn at the presurgery consultation, usually on the day 
before surgery and at three months and six months ± 2 weeks after the ovarian surgery. 
All samples in study I (papers II-III) were analysed at the Department of Clinical Chemistry’s 
laboratory at Karolinska University Hospital. The commercial enzyme-linked immunosorbent 
assay kit (ACTIVE AMH gen II ELISA, Beckman-Coulter Inc. Webster, USA) was used. All 
blood samples were centrifuged within four hours and then sent to the laboratory. Serum 
samples were stored for up to 24 hours in a refrigerator and thereafter in a freezer at -70°C. 
All stored samples were analysed sequentially within one week. Median time for analyses 
was six days. The lowest detectable AMH value of 0.16 µg/L changed to <0.20 µg/L during 
2011. All values of <0.16 µg/L obtained between the 14th of March 2011 and the 2nd of 
March 2012 (N=13) were changed and recorded as <0.20 µg/L for appropriate comparisons. 
The intra-assay and inter-assay coefficients of variation were 5.4% and 5.6%, respectively.  
In paper III, the AMH samples at the two-year follow-up were treated in the same way, with 
centrifugation within four hours and storage at -70°C. These AMH samples were analysed in 
four batches.  
5.4.4 Antral follicle count (AFC) (paper II) 
AFC was calculated as the total number of follicles between 2 and 9 mm. The investigation 
was performed with vaginal ultrasound. Nineteen women had an AFC performed at the pre- 
surgery visit by the gynaecologist in charge of that visit and at the six-month follow-up visit, 
all ultrasound examinations were performed by the same examiner (TL). 
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5.4.5 ART treatment study II (paper IV) 
The women in this study underwent IVF/ICSI treatment either with long down-regulation 
GnRH-agonist protocol or GnRH antagonist protocol. In the long down-regulation protocol, a 
GnRH agonist (nafarelin Synarela; Pfizer 400 µg twice daily or buserelin Suprecur; Sanofi 
Aventis; 0.3 mg nasally three times a day) was administrated for two to three weeks, after 
which ovarian stimulation was initiated with gonadotropin, either rFSH, such as follitropin 
alfa (Gonal F; Merck Serono), follitropin beta (Puregon; Organon) or hMG (Menopur, 
Ferring). In the antagonist protocol, gonadotropin was initiated on menstrual cycle day two to 
three, and a GnRH antagonist was added (cetrorelix Cetrotide; Merck Serono or Ganirelix 
Orgalutran, Organon). The gonadotropin dose was individualized according to women’s age, 
ovarian reserve and antral follicle count. An hCG injection (Pregnyl) or recombinant hCG 
(Ovitrelle, Merck Serono) was given subcutaneously for final oocyte maturation, when at 
least three follicles were 17 mm in size or larger, and oocyte retrieval was performed 36-37 
hours later. Oocyte retrieval was carried out by transvaginal ultrasound puncture. Luteal 
phase support was given with micronized progesterone (Progesteron MIC, APL) or vaginal 
gel (Crinone, Merck Serono) until the day of the pregnancy test. The pregnancy test was 
performed 14 days after embryo transfer, and if positive, an ultrasound examination was 
performed at pregnancy week seven to nine. All biochemical pregnancies (positive pregnancy 
test but no confirmed pregnancy on ultrasound) were classified as negative in this study. Only 
ultrasound-verified pregnancies at week seven to nine were considered positive in calculating 
clinical pregnancy rates for this study. 
The secondary outcome variables were as follows: ovarian sensitivity index, oocytes 
retrieved, supernumerary embryos obtained per treatment cycle and embryo score. Embryo 
score was calculated using the integrated morphology cleavage embryo score (IMC) (138) at 
two out of three clinics (Reproduction Centre Uppsala University Hospital and Reproductive 
Medicine Karolinska University Hospital). Reproductive Centre Uppsala University Hospital 
uses ESHRE’s guidelines for cleavage embryos (139). 
IVF was performed in 54 % of the cases, and ICSI or combined IVF/ICSI was performed in 
the remaining 46 %. About half of the women received one treatment only, including both 
those exposed with a history of unilateral oophorectomy (n= 44, 57.9 %) and controls (n= 
7103, 55.1 %). A few women with UO underwent up to six IVF/ICSI treatments, and among 
women with two intact ovaries, a few underwent up to 10 IVF/ICSI cycles. 
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5.4.6 Reproductive outcome 
Primary outcomes were clinical pregnancy rates after oocyte pick up (OPU) and after embryo 
transfer (ET), both in fresh cycles, and cumulative clinical pregnancy rate, including both 
fresh and thawed cycles. The secondary outcome was live birth rate (LBR), both after fresh 
cycle and cumulative, measured by OPU and ET.  
5.4.7 Ovarian sensitivity index 
The OSI was used to evaluate ovarian responsiveness. The OSI is defined as the 
responsiveness to ovarian stimulation, as measured by a ratio of the total number of oocytes 
retrieved and total dose of FSH administrated (140-142). The OSI is particularly useful as 
women in IVF/ICSI cycles are often treated with different stimulation regimes. The women 
were categorized into three different groups (poor, normal and high responders) after a 
normogram of OSI response (141). 
5.5 STATISTICS 
5.5.1 Paper I 
FPI sub-scores were calculated using a 6-point Likert scale and interpreted as indicating low, 
average, moderately high or very high levels of infertility-stress based on norm values for 
individuals seen for infertility treatment (136). Responses to questions with an open-response 
format were analysed according to content and categorized into groups. The VAS-scores for 
distress and satisfaction were dichotomized according to the median value, which was five 
(<5 and ≥5). Univariate logistic regression analyses were performed to investigate the 
relationship between socio-demographic data, clinical data and reproductive desire/worry and 
the outcome variable (perceived information about potential impact of surgery on fertility). 
Independent statistically significant variables (desire for children and age dichotomized as 
<35 or ≥35) and variables selected for their potential importance regarding information given 
to patients (parity and education level) were entered into a multivariate logistic regression 
model. All statistical analyses were performed using PASW Statistics 19 (SPSS Inc., 
Chicago, IL). Statistical significance was set to a p-value of 0.05. 
5.5.2 Papers II and III 
Baseline characteristics were presented as absolute and relative frequencies with either means 
and standard deviations (SD) or medians with ranges, as appropriate. The distribution of 
AMH levels were skewed when tested with the Shapiro-Wilks test. Wilcoxon’s signed-rank 
test was used to test the significance of differences in AMH levels over time. The Mann-
Whitney U test and Kruskal-Wallis H test were used to compare AMH and AMH 
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concentration changes over time. The percentage of change was calculated as (AMH baseline 
– AMH 6 months)/AMH baseline and (AMH baseline – AMH 2 years)/AMH baseline. 
Kendall’s tau correlation coefficient was used to investigate correlations between AFC, AMH 
and age.  
5.5.3 Paper II 
All baseline AMH levels were categorized into three groups (≤1.1, 1.2–4 and >4 µg/L). The 
women’s groups were defined as having low, normal and high AMH concentrations. This 
categorization was done to see if percentage changes over time differed according to the 
women’s baseline level of AMH. A multivariate regression analysis used baseline AMH 
levels, age, cyst size, duration of surgery and assessed intra-operative bleeding as covariates 
to identify predictors for AMH decrease at three and six months. 
All statistical analyses were performed using PASW Statistics 19 software (SPSS Inc., 
Chicago, IL, USA). Statistical significance was set at a two-tailed p-value of 0.05. 
5.5.4 Paper III 
To study differences in pregnancy rates according to AMH changes at six months, the women 
were categorized into three groups. Group A included women with low ovarian reserve with 
baseline AMH levels <0.7 µg/L which remained low after surgery. They were informed that 
low AMH levels are associated with reduced fertility. Group B included women with 
normal/high baseline levels that remained within the normal range. They were informed that 
their normal ovarian reserve, estimated by AMH levels, remained within normal range after 
surgery and that fertility should not be affected. Group C had similarly normal/high baseline 
levels that were reduced by 30 % or more at six months. The women were informed of a 
reduction in their AMH concentrations, but reassured that their levels were still within the 
normal range. A one-way Anova test, Kruskal-Wallis test and Pearson’s chi-squared test were 
used to compare subgroups based on the desire for additional children at baseline, AMH 
subgroups and attempting pregnancy. The Mann–Whitney U test was used to compare AMH 
values and AMH concentration changes over time between groups in terms of histopathology 
(endometriomas vs non-endometriotic cysts), pregnancy or AMH group categories. 
All statistical analyses were performed using PASW Statistics 21 software (SPSS Inc., 
Chicago, IL, USA). Statistical significance was set at a two-tailed p-value of 0.05. 
5.5.5 Paper IV 
Generalized estimating equations (GEE) models (143) were utilized, as two-thirds of the 
women had more than one treatment when including both fresh and thawed treatments. This 
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regression model makes it possible to take into account the dependence between repeated 
treatments for each woman. The same women can thus be included at different time points. 
The GEE model was used for continuous and dichotomous outcomes with and without 
adjusting for age, OSI and clinic. Effect measures were mean differences and odds ratios for 
continuous and dichotomous outcomes, respectively (with 95 % confidence intervals and p 
values with statistical significance set at p < 0.05 for two-sided tests). Effects were assessed 
in univariate and in multiple models while adjusting for women’s age, ovarian sensitivity and 
clinic. An OSI normogram was used to categorize the women into three groups (141). 
Statistical analyses were undertaken with the SAS statistical program 9.4, SAS Institute. 
6 ETHICAL CONSIDERATIONS 
We followed the ethical standards of the Helsinki Declaration of 1975, which was revised in 
2000. All participating women in the prospective cohort study were informed about the 
research and the current lack of knowledge about the potential impact of ovarian surgery on 
the ovarian reserve. They received both oral and written information about the study, and all 
participating women signed a formal consent. For the follow-up visits, they were contacted 
twice by telephone or by post. All women also received information regarding their 
individual AMH concentrations and any changes in these concentrations some weeks after 
each blood test. Knowledge of their individual AMH concentrations did not influence the 
type of ovarian surgery they underwent or their treatment in any way, as the AMH 
concentrations were not known at the time of surgery. There was only one woman in the 
study who preferred not to receive any information about her ovarian reserve. 
In study IV, the clinical data was prospectively collected as part of the women’s IVF/ICSI 
treatment protocols. The data was then anonymised and analysed at the group level.  
All studies were approved by the Regional Ethical Review Board in Stockholm, Sweden: 
Study I (papers I-III) (D-nr 2011/107-31-4, 2012/314-32, 2013-532-34) and study IV (D-nr: 
2011/1758-31-2, 2014/1360-32). 
7 RESULTS 
Study I included a cross-sectional design, and a prospective cohort followed for 3, 6 and 24 
months, as reported in three papers. The participants’ age and percentage of endometriomas 
were similar in the three different papers (papers I-III). Comparison showed no significant 
difference between study participants and women who were lost to follow up at 24 months in 
terms of their desire for children (paper III).  
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Table 7. Women’s age and reproductive history among participants in study I. 
Paper I II III 
Women (n) 
106 75 
66 
Age, mean (SD) 
32.3(6.4) 32.1 (6.2) 32.5 (6.4) 
Children, n (%) 
42 (39.6) 30 (40) 24 (36.4) 
Infertility (%) 
20 (18.9) 15 (20) 
14 (21.2) 
Endometriomas (%) 
33 (31.3) 25 (33.3) 21 (31.8) 
SD: Standard Deviation 
7.1.1 Paper I 
Only half of the women (n=51) reported that they had received information about the 
potential impact of ovarian surgery on their fertility. In a multivariate logistic regression 
model, desire for children was the only variable significantly associated with having received 
such information (p=0.02). Women who desired children were three times more likely to 
recall having received information about the impact of surgery on fertility compared to 
women with no such desire. Among the women who had received any fertility-related 
information about the surgery, 26 women (59 %) recalled receiving information that ovarian 
surgery could potentially have a negative impact on future fertility, and 20 (39 %) 
remembered receiving information about a lack of negative impact on fertility. Only 10 % of 
the women in our study population stated that fertility-related information was unnecessary 
for them. 
About half of the participating women (N=57) reported moderate or high levels of worry 
about future fertility (VAS ≥5). Furthermore, among women with a desire for future children 
(n=76), high levels of distress were reported for the following FPI subscales: Need for 
parenthood (12 %) and Rejection of a child-free lifestyle (20 %). 
7.1.2 Paper II 
In this paper, we described the changes of AMH observed after ovarian surgery within a 
six-month follow-up period. Based on baseline levels prior to surgery, there was a 
significant decline of AMH in the entire group of women. This statistically significant 
decrease was evident at three and six months. Median AMH levels decreased significantly 
from 2.7 µg/L (0.2-16.9) to 1.6 µg/L (0.2-9.9) at three months and were still low, 1.6 µg/L 
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(0.2-8.3), at six months (p<0.001, respectively). Women with normal baseline AMH 
concentrations (1.2–4 µg/L) or elevated AMH (>4 µg/L) showed a higher decrease of AMH 
levels at the six-month follow up compared to women with low AMH levels at baseline 
(≤1.1). We found a difference in the reduction of AMH concentrations according to the 
histopathology of the cysts. In the case of endometriomas, we observed the highest median 
reduction at six months (a reduction of 50 %). Women with dermoid cysts presented with a 
smaller reduction (25 %), and women with follicular cysts or cystadenomas showed a 34 % 
reduction of AMH levels. The study group was heterogeneous with regard to the surgical 
technique applied to removing the cysts: 65 women had a cyst enucleation, four had a 
resection of ovarian tissue, four had a unilateral oophorectomy, and two had surgery for 
bilateral cysts.  
In order to follow changes in AMH concentrations, sub-analyses in a more homogenous 
group were performed. This group included only women with a clean cyst enucleation 
surgery without any obvious removal of ovarian tissue during the surgery. 
 
Figure 12. Comparison of women with endometriomas vs non-endometriotic cysts. This figure illustrates 
AMH concentrations in 41 women who had a clean ovarian cyst enucleation for a single cyst and who had no 
previous ovarian surgery. There was one outlier: a woman in the non-endometriotic group who had a baseline 
AMH of 17 was removed to make the boxplot easier to comprehend. There was a significant decline in AMH 
at six months in the non-endometriotic cysts group (p=0.002), but this was not observed in the endometriotic 
group (p=0.060). 
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7.1.3 Paper III 
This part of the study aimed to investigate pregnancy outcomes in relation to changes in 
AMH concentrations following ovarian surgery. During the study period, 26 women tried to 
conceive, and 15 achieved pregnancy (58%). The live birth rate was 46 %. A high percentage 
(82 %, n=9) of the women who tried to conceive without success had also reported fertility 
problems prior to surgery. Eleven women received some form of infertility treatment, which 
resulted in five live births. The treatments were as follows: one ovulation induction treatment 
with clomiphene citrate, one intrauterine insemination and one oocyte donation. Eight women 
received treatment with IVF/ICSI. Women with normal AMH concentrations at baseline who 
had a small or no reduction at six months showed the highest live birth rate of 62%. Among 
women who tried to conceive, there were no children born in the group of women with low 
ovarian reserve (AMH <0.7 µg/L) using their own oocytes compared to a live birth rate of 
about 50% among women with normal/high AMH levels (p=0.070). 
Serum AMH decreased in the whole group from 2.7 µg/L (0.2-16.9) to 2.0 µg/L (0.2-11) at 
six months and continued to decrease to 1.0 µg/L (0.2-20.7) at the two-year follow up (p = 
0.001, respectively).  
7.1.4 New subgroup analyses for this thesis 
The new subgroup analyses included only women who attended all three follow-up visits at 
3, 6 and 24 months (Figures 13-15). AMH levels decrease significantly after surgery for 
endometriomas and non-endometriotic cysts at 6 and 24 months postsurgery, respectively. 
The result was similar when including women (n=46) who had different types of ovarian 
surgery (cyst enucleation, fenestration or resection/unilateral oophorectomy) (Figure 13) and 
women (n= 32) who had a clean cyst enucleation (Figure 14). A significant reduction of 
AMH levels at three months was only demonstrated among women who had surgery for non-
endometriotic cysts.  
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Figure 13. Comparison of median AMH levels between women with endometriomas vs non-
endometriomas who attended all four visits. The figure illustrates the women (n=46) who attended presurgery 
and 3-, 6- and 24-month follow-ups. Four of the women had a fenestration of a cyst, two a resection/unilateral 
oophorectomy and 40 a cyst enucleation. P value between AMH levels presurgery and each of the follow-ups at 
3, 6 and 24 months. * p<0.05 
 
Figure 14. Median AMH concentrations and changes over time in the 32 women who had a clean 
cystenucleation and completed all four AMH estimations (baseline, 3, 6 and 24 months). Women who were 
breastfeeding, pregnant or had previous ovarian surgery were excluded (n=8). Wilcoxon’s signed-rank test was 
used to test the significance of differences in AMH levels between presurgery and 3, 6 and 24 months. There 
was no significant difference in the percentage of AMH change between the women with endometriomas and 
those with non-endometriomas at 6 or 24 months. * p<0.05 and ** p<0.01. 
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Figure 15. Median AMH by category groups depending on baseline AMH concentrations and their 
changes after ovarian surgery in the 32 women who completed all four AMH follow-up estimations 
(baseline, 3, 6 and 24 months). Women who were breastfeeding or pregnant at time of follow up were 
excluded (n=8). Wilcoxon’s signed-rank test was used to test the significance of differences in AMH levels over 
time. * p<0.05 and ** p<0.01. 
 
7.1.5 Paper IV 
This study aimed to investigate if the clinical pregnancy rates differed in women with a 
history of unilateral oophorectomy (UO) compared to women with intact ovaries.  
Our study showed that women with UO needed higher doses of gonadotropins for 
hormonal stimulation, and fewer oocytes were retrieved at OPU compared to women with 
intact ovaries. The OSI of women with UO was significantly lower than that of women 
with intact ovaries (p=<0.001). Nevertheless, there was no difference in the number of 
supernumerary embryos that could be frozen from the IVF/ICSI treatments or in embryo 
quality between the women with a history of UO and controls. The mean number of 
transferred embryos, including both fresh and thawed treatment cycles, was similar between 
the group of women with UO and controls (1.19 vs 1.16, p=0.198). 
The clinical pregnancy rate/OPU in women with a history of UO was significantly lower 
compared to controls (24.5 % vs 32.4 %) both crude and adjusted for age (p=0.030 and 
p=0.021, respectively). After inclusion of treatments using both fresh and frozen-thawed 
embryos, the cumulative clinical pregnancy rate/OPU was still significantly lower in 
women with UO vs controls: 32.4% vs 42.9% (p=0.031). In a GEE model a 30% reduction 
in the chance of achieving clinical pregnancy was found for women with a history of UO 
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compared to women with intact ovaries, after adjusting for age (Table 8). Even though the 
odds ratio was reduced by 30%, the chance of achieving pregnancy was not significantly 
different after adjusting for age, OSI and clinic. Women with a history of UO also had a 
30% lower chance of achieving live birth after IVF/ICSI treatment compared to women 
with intact ovaries of the same age, but this difference did not reach significance (Table 8). 
 
Table 8. Clinical pregnancy rates and live birth rates (LBR) per OPU and ET in women with a history of 
unilateral oophorectomy; Odds ratios are age-adjusted. 
 Odds ratio 95 % CI P-
value 
Clinical Pregnancy/OPU (fresh) 0.66 0.44-0.99 0.043 
Cumulative Clinical Pregnancy/OPU 
(fresh + thawed) 
0.66 0.45-0.96 0.031 
Clinical Pregnancy/ET (fresh) 0.68 0.45-1.01 0.058 
Cumulative Clinical Pregnancy/ET 
(fresh +thawed) 
0.64 0.42-0.96 0.031 
LBR/OPU (fresh) 0.68 0.43-1.07 0.094 
Cumulative LBR/OPU (fresh+ thawed) 0.71 0.47-1.05 0.090 
LBR/ET (fresh) 0.70 0.44-1.11 0.129 
Cumulative LBR/ET (fresh + thawed) 0.68 0.44-1.03 0.069 
ET: Embryo Transfer, LBR: Live Birth Rate, OPU: Oocyte Pick-Up 
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8 DISCUSSION 
 
In papers II-III, we were able to demonstrate that ovarian cyst surgery significantly reduces 
the ovarian reserve estimated as AMH serum concentration – even for conservative surgery, 
including only cyst enucleations with no macroscopic removal of ovarian tissue. 
The AMH concentration consistently decreased over time at 3, 6 and 24 months post-ovarian 
surgery (paper II-III). For women who underwent conservative ovarian surgery in our clinical 
cohort, the total pregnancy rate was 58 % at the two-year follow-up, including spontaneous 
and ART-pregnancies, among those who tried to conceive (paper III); however, if a whole 
ovary was previously removed, the clinical pregnancy rate was reduced by 30 % after 
IVF/ICSI treatment when compared to age-adjusted women with intact ovaries (paper IV). 
Only about half of the women recalled receiving preoperative information about the impact 
of ovarian surgery on future fertility (paper I). 
 
8.1.1 AMH changes following ovarian surgery 
In our clinical cohort, the reduction of AMH is larger than that shown in normograms of 
women without ovarian surgery. The AMH decreased after all types of ovarian cyst surgery 
(2.7 µg/L to 1.0 µg/L) and also in the subgroup of women who had a clean unilateral 
cystectomy (2.8 µg/L to 0.9 µg/L) within a two-year period (paper III). Normograms of 
fertile women have reported a yearly reduction of AMH of 0.16 µg/L (35) or 5.6 % (34). This 
study is the first with a 24-month follow-up after ovarian surgery reporting not only the 
changes in women’s ovarian reserve as measured by AMH but also fertility outcomes 
(clinical pregnancy rates). As a result, our data cannot be compared to that of previous 
reports. It is important to consider that age-related infertility usually precedes menopause by 
an average of 10 years (13). By using data from a previous study on AMH as a predictor of 
menopause, the ten women in our study with low AMH <0.7 µg/L and a mean age of 36.9 
years would reach menopause at about 43 years (35-47 years) (41). According to another 
study, based on their AMH levels only (AMH <0.7 µg/L), these women would reach 
menopause in a median time of 12 years (95% CI 9.3-12.7) (43). Using the same predictor of 
menopause for the whole group of women who attended the two-year follow-up visit (n=63) 
(mean age 34.5 and median AMH 1.0 µg/L), menopause would be advanced by a couple of 
years: 48 years (40-54 years) (41) and 47.6 years (95% CI 47.3-47.8) (43). There are not yet 
any prospective studies published on the effect of ovarian surgery in terms of ovarian reserve, 
pregnancy rates and age at menopause. 
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The results presented in papers II-III add to the growing body of evidence that ovarian 
surgery affects ovarian reserve measured by AMH concentrations (30, 85, 87, 92-94, 96-98, 
101).  
8.1.2 AMH changes dependent on histopathology type of cysts 
Reduction of AMH after cyst surgery for endometriomas has been described for 3-month (84, 
95, 97), 6-month (87, 94, 96), 9-month (91, 93) and 12-month follow-ups (101). So far, there 
are only four published studies that have compared endometriomas with non-endometriotic 
cysts (84-86, 97). Two of these studies detected a significant reduction in AMH levels in the 
non-endometriotic cyst group as early as one month postsurgery (85, 86). However, these 
studies were relatively small: the first one included seven women with non-endometriotic 
cysts (six dermoid cysts and one cystadenoma) (86), and the second one included 21 women 
with non-endometriotic cysts (18 dermoid cysts, two cystadenomas and one struma ovarii) 
(85). The results of AMH decline three months postsurgery for non-endometriotic cysts are 
more inconsistent. A significant reduction of AMH three months postsurgery was 
demonstrated in only one study including 32 women with non-endometriotic cysts (15 
women with dermoid cysts and 17 cystadenomas/functional cysts) (97). By contrast, Kitajima 
et al (84) showed no significant reduction of AMH in the non-endometriotic cyst group (8 
women with dermoid cysts and 5 cystadenomas) three months postsurgery. Chang et al (86) 
also found no effect at three months despite observing a significant decline of AMH at one 
month. In paper II, we found significant median reductions in AMH concentrations six 
months following ovarian surgery following both surgery of endometriomas (n=20) and 
dermoid cysts (n=31); meanwhile, the median AMH reduction was non-significant in women 
with cystadenomas/functional cyst (n=15). The decline of AMH continued at the two-year 
follow-up, and it was similar for all women: there was no significant difference in median 
decline after surgery between women with endometriomas and non-endometriotic cysts 
(paper III). Researchers have argued that AMH decline after ovarian cyst surgery results from 
the removal of ovarian cortical tissue and ovarian follicles. Indeed, removal of healthy 
ovarian tissue occurs during surgery for ovarian cysts and differences have been 
demonstrated according to cyst histopathology. In the case of endometriomas, up to 54 % of 
healthy ovarian tissue has been removed; in dermoid cysts, the figure is up to 17 %, and in 
cystadenomas, it was 0 % (144, 145). Another study detected that normal ovarian cortex was 
accidently removed in 92 % of women who had surgery for endometriomas; in the non-
endometriotic cyst group, there was diversity according to the histopathology type (146). 
With dermoid cysts, the ovarian cortex was removed in 82 % of cases, and for a corpus 
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luteum hemorrhagicum, it was removed 78 % of the times (146). In one of the largest studies 
published on the effect of ovarian surgery for non-endometriotic cysts, no significant 
difference was detected in follicles accidently removed between endometriomas and non-
endometriotic cysts (97). 
Until recently, there has been a belief that only surgery of endometriomas may affect the 
ovarian reserve, estimated as AMH concentrations. Earlier studies of non-endometriotic cysts 
only showed a decrease at one month (85, 86), which then improved at three months (86); 
another study showed no decrease at all (84). Our study both confirms the results of Kwon et 
al (97) and increases knowledge about the long-term effects on ovarian reserve following 
ovarian surgery. Surgery for non-endometriotic cysts also results in a post-operative decrease 
of AMH concentrations not only at 3 months but also at 6 and 24 months (papers II-III). As 
our study is the largest to date regarding AMH concentrations after surgery in women with 
non-endometriotic cysts (n=47), we were able to divide the group population and compare 
dermoid cysts and cystadenoma/functional cysts separately (paper II). In the two-year 
analysis, there were few women with cystadenoma/functional cysts; therefore, the 
cystadenomas/functional cysts and dermoid cysts were analysed as a group (paper III). In the 
group of women who had unilateral ovarian cystectomy, there was no difference in median 
change in percentage of AMH at 6 or 24 months between endometriomas (n=13), dermoid 
cysts (n=21) and cystadenomas/functional cysts (n=5), but the study sub-groups used for 
these comparisons were small.  
8.1.3 Predictors for AMH changes following ovarian surgery 
Already in 2012, a review article stated that no further research on the effect of ovarian 
cystectomy on endometriomas was needed, as a significant reduction of AMH had been 
demonstrated in several studies (88). Instead, further research on predictors for AMH 
decrease are necessary (88). Research associates bilateral endometriomas as a significant 
factor in AMH decline after ovarian surgery (92, 147). No previous studies, including ours, 
could demonstrate a difference in AMH decline between unilateral or bilateral surgery for 
non-endometriotic cysts (84-86, 147). This might result from the small number of women 
with bilateral non-endometriotic cysts available for comparison that were included in the 
studies, creating a lack of statistical power to detect a difference. In one previous study, 
preoperative AMH levels have been reported to positively correlate with AMH decline 
postsurgery (96). In our study, the only significant predictor for postoperative AMH 
reduction was the AMH concentration at baseline. Postsurgery, women with a higher baseline 
AMH level had an odds for reduction at three months of 1.9 (95 % CI 1.1-3.1), and at six 
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months of 2.5 (95 % CI 1.2-5.2) compared to women with low ovarian reserve <1.1 µg/L. 
These data are presented in paper II.  
8.1.4 AMH changes following ovarian surgery and pregnancy rates  
We could not detect a difference in pregnancy rates for women with normal AMH prior to 
ovarian surgery with regard to the magnitude of the AMH changes over time at the 24-  
month follow-up (paper III). In the women’s group with AMH categorized as low prior to 
ovarian surgery (<0.7 µg/L), none of the women who tried to conceive achieved a pregnancy, 
but one undesired pregnancy occurred among these women. Our results confirm the study of 
Streuli et al (148), which indicated that there is no lower limit of AMH where a spontaneous 
pregnancy cannot occur. Results from previous studies are inconsistent regarding the 
predictive value of a low AMH level on fecundity. In a Danish study of younger women (< 
35 years of age), there were no significant differences in time to pregnancy between women 
with low AMH <0.7 µg/L and women with normal AMH concentrations (56). A similar 
study that included women of an older age (30 – 44 years) showed a significant reduction of 
fecundability (fecundability ratio 0.38; 95 % CI 0.08-0.91) in women with AMH<0.7 µg/L 
(55). Both of the previous studies had a short follow-up period of six months. In our study 
with a longer follow-up period of 24 months, data were inconsistent regarding time to 
pregnancy, as this factor was not optimally assessed (paper III). We can conclude that there 
was a significant difference in pregnancy rates between the group of women with low AMH 
<0.7 µg/L and women with normal/elevated AMH concentrations despite changes in their 
AMH postsurgery (p=0.028) (paper III).  
8.1.5 Pregnancy rates and histopathology of the cyst  
Pregnancy rates did not differ between women with endometriomas and non-endometriotic 
cysts in our study (paper III). Only one previous study demonstrated a difference in 
pregnancy rates within 24 months following ovarian cystectomy for endometriomas (15% 
pregnancy rate) and non-endometriotic cysts (46% pregnancy rate) with a population size of 
104 women (146). Otherwise, previous studies on pregnancy rates have primarily focused on 
women with endometriomas. A meta-analysis including 14 studies of pregnancy rates 
following surgery for ovarian endometriomas showed a weighted mean of 50% and a 
variation in pregnancy rates between 30-67% (149). The authors argue that the true 
pregnancy rate was probably lower due to selection bias, loss to follow up and confounding 
variables. A review article of surgery for borderline ovarian tumours (BOT) report a pooled 
spontaneous pregnancy rate of 54% (150). Unfortunately, results for cystectomy and 
unilateral oophorectomy were mixed, so the pregnancy rate per surgery type was not reported 
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(150). In that review article, the last discussed study reported a similar pregnancy rate 
between the unilateral oophorectomy group (89%) and cystectomy group (86%) in women 
with borderline ovarian tumour stadium 1 (151). No differences in pregnancy rates have been 
demonstrated between women who have undergone ovarian surgery or those following 
expectant management of ovarian endometriomas prior to ART (152). Such results have been 
interpreted differently. Some studies advise performance of surgery before ART and others 
point out the potential harm to the ovarian reserve. ESHRE’s 2013 guidelines state that more 
studies are needed, but nonetheless recommend expectant management of painless 
endometriomas prior to ART. They also point out the importance of counselling women 
regarding the risk of losing an ovary and/or ovarian reserve with surgery (105).  
8.1.6 Clinical pregnancy rate following ART in women with UO 
By collecting data from three large Swedish ART centres, we were able to include 76 women 
with a history of UO and 12879 controls, and to demonstrate a 30% reduction of clinical 
pregnancy rates in women with a history of UO, compared to age-adjusted controls (paper 
IV). This is the first study to report a reduced pregnancy rate after IVF/ICSI treatment with 
mostly single embryo transfer in this population. There was also a 30% reduction in LBR in 
the UO group, even though the difference between UO and controls did not reach statistical 
significance. This finding might be explained by the relatively small sample size of exposed 
women, leading to insufficient power in investigating LBR differences. The effect of 
unilateral oophorectomy on female reproduction is still partly unknown and open for 
discussion. It has been shown that women with a history of UO tend to reach menopause one 
year earlier (107, 110). Previous studies of IVF/ICSI treatment in women with a history of 
UO showed no significant differences in pregnancy rates even though the women required 
higher gonadotropin doses, and fewer oocytes were retrieved at OPU (112, 113, 115, 116). 
One possible reason for our finding of a difference in pregnancy rates might be that our 
cohort of women, especially unexposed, was larger than that of previous studies. Embryo 
quality, according to ICM score, was similar between the two groups in our study (138). 
Miscarriage rates did not differ between the two groups. Most studies on women with UO 
have demonstrated a significantly lower amount of oocytes retrieved at OPU (112-116, 121, 
123, 125), which was confirmed by our study. It has previously been concluded that there is a 
relationship between the number of oocytes retrieved, pregnancy and LBR (153). Therefore, 
in line with paper IV, it can be inferred that women with a history of UO might have 
significantly lower chances of pregnancy. 
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8.1.7 Fertility-related information prior to ovarian surgery 
At the time of study I (paper I), a dawning knowledge of the negative effect of ovarian 
surgery on the ovarian reserve began to arise. In 2010, RCOG published guidelines 
highlighting the importance of discussing loss of function with the patient, especially the loss 
of fertility (104). In paper I, only half of the women included in the study recalled receiving 
preoperative information about the impact of ovarian surgery on future fertility. Desire for 
children was the only factor associated with fertility-related information. Several reasons 
might explain this finding. The gynaecologists might have provided fertility-related 
information, but the women failed to recollect it because so much information was provided 
during the visit. Patients might also experience presurgery anxiety affecting their perceptions 
and cognitive capabilities (154). Another explanation might be that the gynaecologists were 
unwilling to unnecessarily worry the patients about what they perceived to be low-risk 
outcomes. Only 10 % of the women included in our study regarded the fertility-related 
information as irrelevant to them. Reproductive knowledge seems to be sparse among 
childless women, both in terms of the consequences of delaying childbearing and the 
effectiveness of ART (4, 155). Several public campaigns have been launched in Great Britain 
and the United States in an attempt to improve fertility awareness. The effectiveness of such 
campaigns remains unclear. Online educational programs have sought to improve people’s 
fertility awareness. Unfortunately, a recent study showed that six months after reading online 
educational information on fertility, participants’ fertility beliefs and knowledge returned to 
pre-intervention levels (156). The lack of reproductive knowledge among women increases 
the risk of not receiving correct fertility-related information regarding the risks of ovarian 
surgery. All doctors must strive for shared decision-making with a well-informed patient 
prior to ovarian surgery (103), especially as reproduction and ability to become a parent is an 
important factor for many women (4). Prior to invasive treatment, information needs to be 
provided using structured communication tools that present risk to women in a way that they 
can understand. RCOG recommends that doctors inform patients of an event’s probability in 
numbers, not in words (157). 
8.1.8 Ovarian surgery in Sweden and ovarian reserve screening 
In Sweden, there has been an increase in the number of ovarian surgeries performed for 
women aged 15-44 years over the last seven years, from 3000 to 3300 (Figure 8) (83). 
Reasons for this increase might be the improved diagnostic technique (transvaginal 
ultrasound) and the number of private clinics that perform laparoscopic ovarian surgery. This 
trend of increasing ovarian surgeries goes against all newly-published guidelines, which 
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recommend expectant management in benign asymptomatic cysts < 7cm (76-79). A change 
in ovarian surgery policy might occur as knowledge increases about ovarian physiology and 
the long-term effects of ovarian surgery.  
Today, there is variety of ways to help women conceive. Still, if we harm women’s ovarian 
reserve irreversibly through ovarian surgery, there is no guarantee that ART treatment will 
help. Live birth rates after ART treatment is about 37 % in the entire population who reached 
the embryo transfer stage, but younger women have the highest LBR (69).  
Ovarian reserve screening has been advocated by measuring AMH concentrations. Such 
screening would give women a personalized risk profile of her reproductive capacity, and it 
might improve their motivation in reproductive life planning (158). ACOG’s 2015 
recommendation on ovarian reserve testing states that AMH should be measured for women 
over 35 years of age who have not conceived after six months of attempting pregnancy and in 
women who have had ovarian surgery for endometriomas (2). If AMH is diminished or 
decreased, the women should be counselled of their shorter reproductive window. It is hoped 
that such information will help women achieve pregnancy. This information aligns with our 
findings in paper III: we suggest that women with reduced ovarian reserve should be 
informed of their chances to conceive as well as the reduced reproductive window that can be 
estimated in some individual cases. In paper III, we also report that the information provided 
on AMH changes within two years following ovarian surgery did not affect women’s 
reproductive behaviour, and that the information that was provided to the women in this 
study after their ovarian surgeries did not increase patients’ worries about their fertility 
potential. 
8.2 METHODOLOGICAL CONSIDERATIONS 
8.2.1 Study design and validity 
In paper I, we present results from a cross-sectional study of women who completed a 
questionnaire at the presurgery visit. The women answered the questionnaire directly after 
meeting with a gynaecologist to plan for ovarian cyst surgery. A strength of the study was 
that the assessment of the women’s perceived information was done so quickly after 
consulting with the gynaecologist, decreasing the risk of recall bias. A disadvantage is that 
we could not study the extent to which doctors actually gave fertility-related information, as 
we did not perform a parallel survey asking the gynaecologists about their information 
disclosure routines. Information prior to surgery is standardised at the clinic, and all doctors 
were aware of the present study, which might lead them to provide more detailed information 
about the effects of ovarian surgery on fertility.  
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The response rate in the study was relatively high (80%). Only 20 women declined 
participation, and six women did not complete the questionnaire. Because not all women 
answered or filled out the questionnaire, there is a risk of selection bias. It might be that 
women with a desire for children were more prone to participate in the study. This might 
imply that the true proportion of women with a desire for children is lower than reported. 
Södersjukhuset, where the study was undertaken, is a tertiary care center that receives a 
variety of women from the population, not just infertile women. This makes the study more 
representative and increases its generalizability.  
Because knowledge about the effect of ovarian surgery on ovarian reserve has increased 
during the last couple of years, it would have been interesting to study if there was a 
difference in the percentage of received fertility-related information prior to surgery over this 
time period. Unfortunately, the inclusion time of a year was too short to study this time 
dimension. Today, with more widespread knowledge, the results of our study might be 
different. 
In papers II-III, we present results from a prospective cohort study. This design was useful as 
we could study the relationship between exposure (ovarian surgery for cysts) and outcome 
(AMH changes over time and pregnancy rates). It would have been unethical to randomize 
women to surgery or not, as all cysts were symptomatic. A possible confounder was age, as 
women who had a unilateral oophorectomy were older, and age affects AMH levels. To 
adjust for this possible confounder, we used multivariate logistic regression. Another strength 
of this study was a longer study period compared to previous studies; in addition, both 
ovarian reserve and pregnancy outcome was measured. The reliability of Beckman Coulter 
Gen II ELISA AMH kit was questioned during the study period. As described earlier, fresh 
AMH samples have been found to increase progressively in room temperature, but all AMH 
levels in our study were analysed from frozen samples with a median freezing time of six 
days; therefore, the risk of false values was minimized. Another strength is that all AMH 
samples were analysed in the same laboratory with low intra- and inter-assay coefficients of 
variability.  
In prospective cohort studies, there is always a risk of selection bias due to loss to follow-up. 
In paper II, 72 % of the women attended both the 3- and 6-month follow up. The other 21 
(28%) women attended either the 3- or the 6-month visit. No difference was demonstrated 
regarding age, baseline AMH or desire for children between the women who attended both 
the 3- and 6-month follow ups compared to the women who only attended one of these visits. 
Seventeen women (20 %) were lost to follow up in paper III. Analysis of these women 
showed that they had the same age, desire for children, baseline AMH concentrations and 6-
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month AMH concentrations as the women who completed the two-year follow-up visit. 
Therefore, the risk of selection bias was probably low, and a representative group of the 
women attended all follow-up visits. Our results on ovarian reserve following ovarian surgery 
do not seem to depend on chance or so-called random errors, as a statistically significant 
reduction of AMH was demonstrated in all three follow-up analyses of AMH. Because these 
operations are generally performed in a similar way, external validity is high and applicable 
for the general population of women in Sweden who attend a university hospital where 
residents operate together with consultants in gynaecology.  
Study IV is a population-based registry study. A retrospective registry study has inherent 
problems because the available information is restricted to the register’s content on exposure, 
outcomes and confounders. When using retrospective data, the researcher also naturally 
depends on the quality of the data in the registry. A strength in our study is that it is 
multicentre, and that the same type of database was used by all three clinics. In this way, all 
variables regarding clinical features, embryology charts and IVF/ICSI treatment aspects were 
registered similarly, whit a minor risk for misclassification. A disadvantage was that no 
detailed information was available regarding the reason for ovarian surgery or pathology of 
the cysts. All presented data was age-adjusted, as age was considered a confounder. In study 
IV, the risk of selection bias was reduced because data on all exposed and unexposed women 
in the study cohort were collected from three ART centres. Further, the outcome variables, 
clinical pregnancy rate and live births rate, are reported to a national quality registry where 
validation is conducted on a regular basis. The quality register has 100 % coverage for 
patients and clinics. If data is incomplete or missing, the IVF clinic is informed, so the data 
can be completed. This strengthens our results, as the outcome variables have no missing 
values. External validity and generalizability are high as the treated women at the three 
different ART clinics were of different ages. In addition, they had different reasons for 
infertility and received similar treatment protocols for IVF/ICSI. Two of the clinics are 
funded through public health care, so the treatment is affordable for most patients, thus 
minimising socioeconomic differences.  
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9 CONCLUSION 
Ovarian cyst surgery, even conservative, is associated to a reduction of the ovarian reserve 
and might affect pregnancy rates, at least for women receiving IVF/ICSI treatment after 
unilateral oophorectomy. Fertility issues must be discussed with women before they make the 
decision to have ovarian surgery.  
9.1 CLINICAL IMPLICATIONS 
Ovarian cyst surgery induces a significant reduction in ovarian reserve, which remains at 
least two years following surgery. However, the potential to conceive might be maintained in 
the sub-population of women who had normal or high serum AMH concentrations prior to 
their ovarian cyst surgery.  
 
Fertility issues are important for women of reproductive age, and they must be addressed and 
taken into account when women are planning for ovarian cyst surgery. A shared decision 
between the gynaecologists and well-informed patients should be made before invasive 
treatments, such as ovarian cystectomy. Women’s knowledge of eventual risks and 
intervention complications would increase awareness and satisfaction with their healthcare. 
  
AMH should not routinely be assessed prior to ovarian cyst surgery in women of fertile age, 
as our research shows that surgery itself does not seem to impact women’s fertility. However, 
women with decreased ovarian reserve prior to surgery, and older women with an expected 
low ovarian reserve, could benefit from awareness of a shorter fertile window.  
 
Women with a history of unilateral oophorectomy should also be informed of the expected 
reduced number of eggs collected for IVF/ICSI treatment and the reduced likelihood to 
achieve clinical pregnancy by ART treatment. 
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9.2 FUTURE RESEARCH 
A larger cross-sectional study regarding presurgery information would be beneficial in terms 
of what information women need and what information they perceive. This phenomenon 
could be studied using questionnaires/interviews with gynaecologists regarding what 
information they think is of importance to women. Similar questionnaires/interviews should 
be given to women with ovarian cysts to ascertain which information they find important. 
The presurgical visit could be recorded to actually interpret given and received information. 
The study could also include a follow-up interview with the women a few weeks following 
surgery about the given information and its adequacy. The level of anxiety should be 
measured to see if there is a possible association between anxiety and received information.  
 
Studies of AMH ELISA assay methods could ensure their standardisation, including limits of 
normal AMH values. Such research would enable further studies to be more comparable. 
 
Cohort studies of AMH concentrations and changes over time in a general population of 
women would assist in constructing normograms of AMH. These normograms should be 
accurate enough to predict women’s future reproductive time span and menopause with a 
narrower confidence interval than earlier studies.  
 
A prospective cohort multicentre study including women of reproductive age with different 
histopathology types of ovarian cysts would enable us to increase our knowledge regarding 
the effects of ovarian cysts treated conservatively or through ovarian surgery. Exposure 
should include different types of ovarian surgery, such as cystectomy, ovarian resection and 
unilateral oophorectomy. If possible, these women should be followed up with using yearly 
AMH samples, ultrasound and questionnaires regarding their reproductive behaviour for 10 
years or until they reach menopause. Ideally, there would also be a control group of women 
without ovarian cysts included in the study. 
  
Another research approach for learning more about the consequences of unilateral 
oophorectomy would be a register study including all women with a history of unilateral 
oophorectomy and aged-matched controls. The outcome variable would be parity. 
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10 SAMMANFATTNING PÅ SVENSKA 
Vid födseln har kvinnan ungefär sex miljoner oocytanlag (ägganlag) i ovarierna 
(äggstockarna). Av dessa kommer de flesta självdö. Vid menstruationsdebut finns endast 400 
000-600 000 oocyter (ägg) kvar. Minskningen av oocytanlag fortsätter sedan successivt. 
Under kvinnans fertila period kommer ungefär 450 av folliklarna (äggblåsorna) som 
oocyterna ligger i ha ägglossat och de andra, både folliklar och oocyter, kommer 
tillbakabildas. Ovarialreserven (antalet omogna ägg i äggstocken) speglar möjligheten för 
kvinnan att bli gravid. Förlusten av oocyter är åldersberoende och hastigheten ökar 10-12 år 
innan menopaus inträder. Vid 50-års ålder är det så lite kvar av ovarialreserven att 
klimakteriet inträder. Då återstår endast några hundra till tusen folliklar. I Sverige är 
medelåldern för menopaus 51år.  
De mest pålitliga metoderna för att förutbestämma en kvinnas ovarialreserv och hennes 
möjliga svar på fertilitetsbehandling vid provrörsbefruktning är att mäta antalet folliklar 
(AFC) med ultraljud och att genom ett blodprov mäta Anti-mülleriskt hormon (AMH). 
AMH utsöndras endast från de små, < 6mm, folliklarna i ovariet och minskar med stigande 
ålder varför det anses vara en bra markör för ovarialreserven. AMH tycks även vara en god 
prediktor för menopaus. Fördelar med AMH är att det oftast inte är någon interindividuell 
skillnad så provet kan tas när som helst i menscykeln. 
Godartade cystor på ovariet är vanligt förekommande. I Sverige sker årligen cirka 3300 
operationer på grund av cystor i ovariet på kvinnor i fertil ålder. Operationerna har blivit mer 
fertilitesbevarande och idag görs det främst lapraskopiska cystektomier (borttagande av 
cysta) och inte borttagande av en del eller ett helt ovarium vilket tidigare var vanligare. 
Studier har visat att ovarialreserven mätt genom AMH sjunker efter en operation av cystor, 
särskilt vid operation av endometrios cystor. Det är dock oklart om ovarialreserven påverkas 
vid operation av andra sorters cystor, på längre sikt än några månader och ifall kvinnans 
möjlighet att bli gravid påverkas av cystoperation. 
I artikel I, redovisas en tvärsnittsstudie, i vilken 106 kvinnor som skulle genomgå operation 
av ovariet på grund av godartad cysta inkluderades. Kvinnorna fick svara på en enkät med 
frågor av socioekonomisk karaktär, frågor om reproduktion och barnönskan samt frågor om 
vilken information de fått angående deras planerade operations eventuella påverkan på 
förmågan att få barn. I svaren framkom att bara hälften av kvinnorna sade sig ha fått 
information om cystoperationens eventuella påverkan på deras förmåga att få barn. En aktiv 
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barnönskan hos kvinnan var den enda faktorn som ökade chansen för att kvinnan skulle ha 
fått information om operationens eventuella påverkan på hennes fertilitet. 
I artikel II, redovisas en prospektiv kohort studie som följde 75 kvinnor som genomgått 
cystoperation på ovariet. AMH togs före samt tre och sex månader efter operationen. En 
signifikant sänkning av AMH kunde påvisas från 2.7 µg/L (0.2-16.9) till 1.6 µg/L (0.2-9.9) 
vid 3 månader och till 1.6 µg/L (0.2-8.3) vid 6 månader (båda p<0.001). 
I artikel III redovisas en prospektiv kohort studie med två års uppföljning av samma kvinnor 
som deltog i artikel II samt ytterligare 8 kvinnor som endast genomgått öppnande av en cysta 
(fenestration). Sammanlagt inkluderades 66 kvinnorna som svarade på en enkät med frågor 
om barnönskan, graviditeter och antal födda barn sedan operationen. Nytt AMH analyserades 
också. AMH sjönk från 2.7 µg/L före operationen till 2.0 µg/L vid sex månader och till 1.0 
µg/L vid två år efter operationen (p = 0.001 för båda). Hos kvinnor som försökte bli gravida 
efter genomgången operation, både spontant och med hjälp av provrörsbefruktning, var 
graviditetsfrekvensen 58 %. 
I artikel IV redovisas en multicenterstudie från tre IVF kliniker (IVF-provrörsbefruktning). 
Inkluderade var 76 kvinnor som genomgått borttagande av ett ovarium före sin IVF 
behandling. De 76 kvinnorna jämfördes med 12879 kontroller som också hade genomgått 
IVF/ICSI behandling under samma tidsperiod och på samma IVF kliniker.  Möjligheten att 
bli graviditet var 30 % lägre hos kvinnor som tidigare genomgått borttagande av ett ovarium 
jämfört med kvinnor i samma ålder vid behandling med IVF/ICSI. De kvinnor som tidigare 
genomgått borttagande av ett ovarium behövde dessutom högre doser av hormonstimulering 
vid provrörsbefruktningen och färre ägg togs ut vid äggplock.  
Slutsats: I denna avhandling framkommer att ovarialreserven mätt genom AMH minskar efter 
operation av olika sorters godartade cystor och inte bara efter operation av endometrios 
cystor. Ungefär hälften av kvinnorna som försökte bli gravida efter operationen lyckades. 
Borttagande av ett helt ovarium tycks påverka så att det vid provrörsbefruktning kan vara 
svårare att bli gravid. Mer kunskap behövs om effekten av cystoperation på kvinnors fertilitet 
så att kvinnor kan får noggrann och adekvat information om eventuella fertilitetsrelaterade 
risker med en operation.  
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